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Volumetric Modulated Arc Therapy (VMAT) is a new type of Intensity Modulated Ra-
diation Therapy (IMRT) technique as it can deliver a more accurate shape of sculpted
3D dose distribution to the targeted tumour volume in a single 360◦ gantry rotation or
multiple sub-arcs. This improvement, however, has not mitigated the problem of doses
to normal tissues outside the treated volume. The out-of-field dose associated risks re-
mains high clinical and scientific interests for investigations. A re-evaluation of the eye
lens radio-sensitivity by the ICRP 2011 has resulted in a significant reduction of the
threshold for lens opacities from 8 Gy to 0.5 Gy [1]. The objective of this thesis study
is to investigate the out-of-field doses to critical structures such as eye lens and CIEDs
(cardiac implantable electronic devices) such as pacemakers and ICDs during 6 MV
VMAT treatment of the prostate.
In order to provide an accurate estimation of the out-of-field dose to the eye lens and
CIEDs, the out-of-field dose distribution for a Varian iX 6 MV VMAT at St George
Cancer Care Centre was extensively measured and examined while the individual out-
of-field dose components (patient scatter, collimator scatter and head leakage) were
carefully characterised as well. The out-of-field dose profiles with different field sizes
and collimator angles were measured at depths of 5 mm, 15 mm and 37.5 mm, using
an ionisation chamber within a motorised water tank, and compared with the previous
studies in IMRT. The depth-dose measurements were made with a Roos parallel plate
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chamber in solid water at distances of 52 cm and 76 cm from central axis. The dose to
the eye lens and upper chest (typical location of a CIED) from clinical 6 MV VMAT
treatment of the prostate were measured on an anthropomorphic phantom with a cylin-
drical chamber placed at a depth of 3 mm. This depth was chosen to match the depth of
the most radio-sensitive region of the eye lens, which is at a depth of 2-4 mm [2] and a
typical depth of the anterior surface of a CIED.
Our experimental results showed that at distances close to the field edge phantom scatter
was a dominant source of out-of-field dose, while at distances greater than 20 cm head
leakage was the dominant source of out-of-field dose. This result was seen across all the
examined cases for different field sizes, collimator angles and depths of measurement.
Furthermore, using clinical prostate patient VMAT plans the maximum dose received
by the eye lens was found to be 10.8±0.3 cGy, and the maximum dose received to the
chest was found to be 12.3±0.4 cGy for the whole treatment. As expected, the doses
to the eye lens and CIEDs are well below the recommended threshold doses of 50 cGy
for the eye lens [1] and 200 cGy for limits of CIEDs [3]. These indicate that the VMAT
patients receiving prostate treatment will not be at risk of cataracts or CIED failure as
the out-of-field dose is minimal.
However, this work has shown that doses may be higher than predicted by most plan-
ning systems as they do not accurately model photon or electron leakage/scatter from
the LINAC head.
This thesis is dedicated to my late grandmother.
Statement of Originality
This is to certify that the work described in this thesis is entirely my own, except where
due reference is made in the text.







It would not have been possible to write this thesis without the help and support of cer-
tain people, which I would like to mention here.
First and foremost I would like to thank my grandmother, for her unconditional love, for
her wisdom and teaching me strength, in order to fulfill my goals. Thank you for being
the light of my life.
To my mother, thank you for providing me with unfailing support and continuous en-
couragement throughout my years of undergraduate and postgraduate study and through-
out the entire process of my life. For being there whenever I needed it, for supporting me
financially and for always having confidence in me throughout my education. I greatly
appreciate everything you have done
To my family, thank you for keeping me harmonious throughout my years of study
at the University of Wollongong.
To my supervisors, Anna Ralston, Dr.Dean Cutajar, and Dr.Yujin Qi, thank you for




I would like to express my deep gratitude and thanks to my supervisor, Anna Ralston
for imparting her knowledge and expertise and teaching me so many skills that will be
of benefit to me in the field of Medical Physics.
I would also like to thank my supervisors, Dr. Dean Cutajar and Dr. Yujin Qi for
your guidance and for steering me in the right direction whenever I needed it. Your
guidance and supervision are much appreciated.
To the staff at SGCCC, thank you for making my time at St George Cancer Care Centre
a memorable and great one.
I would also like to acknowledge Professor Anatoly Rozenfeld. His encouragement
and support for the students of the Centre for Medical Radiation Physics (CMRP) to
carry out projects and be able to contribute to the world of medical physics.
Contents
1 Introduction 1
1.1 Research Scope and Aims of this Thesis . . . . . . . . . . . . . . . . . 4
1.2 Thesis Structure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2 Literature Review 7
2.1 Prostate Cancer and Treatment Options . . . . . . . . . . . . . . . . . 7
2.2 Brachytherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.3 External Beam Radiation Therapy . . . . . . . . . . . . . . . . . . . . 10
2.4 Linear Accelerators . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.4.1 Linear Accelerator Head . . . . . . . . . . . . . . . . . . . . . 19
2.5 Sources and Characteristics of Out-of-Field Dose . . . . . . . . . . . . 21
2.5.1 MLC and Collimator Orientation . . . . . . . . . . . . . . . . 24
2.6 Critical Out-of-Field Regions in Prostate Radiation Therapy . . . . . . 24
2.6.1 Eye Lens: Cataracts . . . . . . . . . . . . . . . . . . . . . . . 24
2.6.2 Chest: Cardiac Implantable Electronic Devices (CIEDs) such
as: Pacemakers and Implantable Cardiac Defibrillators (ICDs) . 26
2.7 Dosimeters for Out-of-Field Dose Measurements . . . . . . . . . . . . 28
viii
CONTENTS ix
2.7.1 Solid State Dosimeters . . . . . . . . . . . . . . . . . . . . . . 28
2.7.2 Ionisation Chambers . . . . . . . . . . . . . . . . . . . . . . . 31
2.8 Current Research Status of Out-of-Field Dose . . . . . . . . . . . . . . 37
2.8.1 Analytical Models for Estimating Out-of-Field Dose . . . . . . 37
2.8.2 Monte Carlo Methods for Estimating Out-of-Field Dose . . . . 38
3 Experimental Challenges and Principles of Measuring Out-of-Field Dose 42
3.1 Experimental Uncertainties: Type A Uncertainties . . . . . . . . . . . . 43
3.2 Experimental Uncertainties: Type B Uncertainties . . . . . . . . . . . . 43
3.3 Combination of Type A and Type B Uncertainties . . . . . . . . . . . . 44
3.4 Uncertainty Estimate for Measurements . . . . . . . . . . . . . . . . . 44
4 Depth-Dose Measurements of Out-of-Field Radiation 49
4.1 Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
4.2 Methodology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
4.2.1 Part I: Calibration of the Photon Beam . . . . . . . . . . . . . . 50
4.2.2 Part II: Quantification of couch scatter . . . . . . . . . . . . . . 51
4.2.3 Part III: Depth Dose Measurements with Roos Chambers . . . . 53
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
4.3.1 Part II: Quantification of couch scatter . . . . . . . . . . . . . . 55
4.3.2 Part III: Depth Dose Measurements with Roos Chamber . . . . 55
4.4 Discussion/Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . 61
5 Characterisation of Out-of-Field Dose Components 63
CONTENTS x
5.1 Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
5.2 Methodology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
5.2.1 Part I: Calibration of the Photon Beam . . . . . . . . . . . . . . 64
5.2.2 Part II: Comparison with Kry et al. (2006) Out-of-field Dose
Profile Measurement . . . . . . . . . . . . . . . . . . . . . . . 65
5.2.3 Part III: Clinically Relevant Out-of-Field Measurements . . . . 66
5.2.4 Part IV: Calibration of Dose Profiles and Depth Dose Measure-
ments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
5.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
5.3.1 Comparison between Measurements and Kry et al. (2006) . . . 70
5.3.2 Separated Components: Head Leakage, Collimator Scatter and
Phantom Scatter . . . . . . . . . . . . . . . . . . . . . . . . . 71
5.3.3 Contribution of Phantom Scatter . . . . . . . . . . . . . . . . . 80
5.3.4 Effect of Varying Depths . . . . . . . . . . . . . . . . . . . . . 81
5.3.5 Effect of Varying MLC Field Size . . . . . . . . . . . . . . . . 87
5.3.6 Effect of Varying Focus to Source Distance (FSD) . . . . . . . 88
5.4 Discussion/Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . 90
6 Out-of-Field Dose to the Eye Lens and Chest for Clinical VMAT Treatments 94
6.1 Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
6.2 Methodology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
6.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
6.3.1 Comparison: Roos chamber and Cylindrical chamber . . . . . . 99
6.3.2 Anthropomorphic Phantom Measurements . . . . . . . . . . . 100
CONTENTS xi
6.4 Discussion/Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . 101
7 Conclusion 103
7.1 Future Work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
Bibliography 106
List of Figures
2.1 Photon Dose Equivalent as a function of Distance from Central Axis for
IMRT of the prostate Kry et al. (2005b) [25]. . . . . . . . . . . . . . . 16
2.2 Dose as a function of Distance from Central Axis for IMRT and VMAT
of the prostate Blais et al. (2012) [22] . . . . . . . . . . . . . . . . . . 17
2.3 Schematic drawing of the internal components of a medical linear ac-
celerator, adapted from [24]. . . . . . . . . . . . . . . . . . . . . . . . 19
2.4 Sources of out-of-field dose from a medical linear accelerator: (1) pa-
tient scatter, (2) secondary collimator scatter; and (3) head leakage. . . . 22
2.5 Diagram of the eye representing the radio-sensitive region of the lens. . 26
2.6 Cross section schematic of a Cylindrical Farmer type ionisation cham-
ber, adapted from [24]. . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.7 Schematic diagram of Parallel-plate ionisation chamber. . . . . . . . . . 34
2.8 Cross section schematic of a parallel-plate ionisation chamber, adapted
from [24]. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
4.1 Quantification of couch scatter: couch in primary field . . . . . . . . . 52
4.2 Quantification of couch scatter: couch out of primary field . . . . . . . 52
4.3 Experimental set-up of Roos chambers . . . . . . . . . . . . . . . . . . 54
4.4 Experimental set-up of Roos chambers in relation the gantry . . . . . . 54
xii
LIST OF FIGURES xiii
4.5 Out-of-Field Depth Dose using Roos chamber, at the location of the eye
lens, with 0.5 cm x 0.5 cm, 10 cm x 10 cm and 20 cm x 20 cm field sizes. 56
4.6 Out-of-Field Depth Dose using Roos chamber, at the location of the
chest, with 0.5 cm x 0.5 cm, 10 cm x 10 cm and 20 cm x 20 cm field sizes. 57
4.7 Out-of-Field Depth dose using Roos chamber, at the location of the eye
lens and chest with 0.5 cm x 0.5 cm field size. . . . . . . . . . . . . . . 58
4.8 Out-of-Field Depth dose using Roos chamber, at the location of the eye
lens and chest with 10 cm x 10 cm field size. . . . . . . . . . . . . . . . 59
4.9 Out-of-Field Depth dose using Roos chamber, at the location of the eye
lens and chest with 20 cm x 20 cm field size. . . . . . . . . . . . . . . . 60
5.1 Experimental set-up of out-of-field dose measurements, for comparison
with the results of Kry et al. (2006) [26] . . . . . . . . . . . . . . . . . 66
5.2 Experimental set-up of the out-of-field dose measurements, inside the
water tank with/out the phantom scatter . . . . . . . . . . . . . . . . . 67
5.3 Roos chamber in solid water at depth 5 mm . . . . . . . . . . . . . . . 69
5.4 Roos chamber in solid water at depth 5 mm, with the presence of phan-
tom scatter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
5.5 Out-of-field dose profile from 6 MV photon beam measurements as a
function of distance from the central axis, at depths of 3.75 cm and
11.25 cm, compared to both measurements and Monte Carlo simula-
tions from Kry et al. (2006) [26]. . . . . . . . . . . . . . . . . . . . . . 71
5.6 Total Scatter Contribution at depth 1.5 cm, Field size 10 cm x 10 cm,
MLCs 10 cm x 10 cm. Maximum uncertainty 6% (95% confidence
interval) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
5.7 Separated Scatter Components at Collimator 0◦, depth 1.5 cm, MLCs
10 cm x 10 cm, Field size 10 cm x 10 cm. Maximum uncertainty for
Total Dose and HL+CS is 6% (95% confidence interval). Maximum
uncertainty for PS is 8.5% (95% confidence interval) . . . . . . . . . . 73
LIST OF FIGURES xiv
5.8 Separated Scatter Components at Collimator 45◦, depth 1.5 cm. Max-
imum uncertainty for Total Dose and HL+CS is 6% (95% confidence
interval). Maximum uncertainty for PS is 8.5% (95% confidence interval) 74
5.9 Separated Scatter Components at Collimator 270◦, depth 1.5 cm. Max-
imum uncertainty for Total Dose and HL+CS is 6% (95% confidence
interval). Maximum uncertainty for PS is 8.5% (95% confidence interval) 75
5.10 Collimator Scatter + Head Leakage at depth 1.5 cm, Field size 10 cm
x 10 cm, MLCs 10 cm x 10 cm. Maximum uncertainty for 6% (95%
confidence interval) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
5.11 Head Leakage: Out-of-field dose profile showing the effect of closing
the MLCs at collimator 45◦, Field size of 10 cm x 10 cm. Maximum
uncertainty 6% (95% confidence interval) . . . . . . . . . . . . . . . . 77
5.12 Head Leakage: Out-of-field dose profile showing the effect of closing
the MLCs at collimator 270◦, Field size 10 cm x 10 cm. Maximum
uncertainty 6% (95% confidence interval) . . . . . . . . . . . . . . . . 78
5.13 Phantom (water) Scatter at depth 1.5 cm, MLCs 10 cm x 10 cm, Field
size 10 cm x 10 cm. Maximum uncertainty for Phantom Scatter is 8.5%
(95% confidence interval) . . . . . . . . . . . . . . . . . . . . . . . . . 79
5.14 Effect of Phantom Scatter: Total Scatter Contribution compared with
Head Leakage and Collimator Scatter. Conditions: Col 0◦, MLC 10 cm
x 10 cm and Field size 10 cm x 10 cm. Maximum uncertainty 6% (95%
confidence interval) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
5.15 Effect of Depth: Total Scatter Contribution. Conditions: Col 0◦, MLC
10 cm x 10 cm and Field size 10 cm x 10 cm. Maximum uncertainty
6% (95% confidence interval) . . . . . . . . . . . . . . . . . . . . . . . 81
5.16 Effect of Depth: Head Leakage + Collimator Scatter Contribution. Con-
ditions: Col 0◦, MLC 10 cm x 10 cm and Field size 10 cm x 10 cm.
Maximum uncertainty 6% (95% confidence interval) . . . . . . . . . . 82
5.17 Effect of Depth: Total Scatter Contribution. Conditions: Col 45◦, MLC
10 cm x 10 cm and Field size 10 cm x 10 cm. Maximum uncertainty
6% (95% confidence interval) . . . . . . . . . . . . . . . . . . . . . . . 83
LIST OF FIGURES xv
5.18 Effect of Depth: Head Leakage + Collimator Scatter Contribution. Con-
ditions: Col 45◦, MLC 10 cm x 10 cm and Field size 10 cm x 10 cm.
Maximum uncertainty 6% (95% confidence interval) . . . . . . . . . . 84
5.19 Effect of Depth: Total Scatter Contribution. Conditions: Col 270◦,
MLC 10 cm x 10 cm and Field size 10 cm x 10 cm. Maximum un-
certainty 6% (95% confidence interval) . . . . . . . . . . . . . . . . . . 85
5.20 Effect of Depth: Head Leakage + Collimator Scatter Contribution. Con-
ditions: Col 270◦, MLC 10 cm x 10 cm and Field size 10 cm x 10 cm.
Maximum uncertainty 6% (95% confidence interval) . . . . . . . . . . 86
5.21 Effect of MLC Field Size: Total Scatter Contribution. Conditions: Col-
limator 0◦, depth 5 mm, Field size 10 cm x 10 cm. Maximum uncer-
tainty 6% (95% confidence interval) . . . . . . . . . . . . . . . . . . . 87
5.22 Effect of FSD: Total Scatter Contribution. Conditions: Collimator 0◦,
MLC size 10 cm x 10 cm, Field size 10 cm x 10 cm, pelvis phantom
moved 5 cm up. Maximum uncertainty 6% (95% confidence interval) . 88
5.23 Effect of FSD:Total Scatter Contribution. Conditions: Collimator 0◦,
MLC size 10 cm x 10 cm, Field size 10 cm x 10 cm, FSD of the pelvis
phantom moved 5 cm up compared with original position. Maximum
uncertainty 6% (95% confidence interval) . . . . . . . . . . . . . . . . 89
6.1 Full anthropomorphic phantom with the location of the ionisation cham-
bers marked . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
6.2 Positioning of the ionisation chambers on the anthropomorphic phantom 97
6.3 Out-of-Field Depth Dose Comparison between Roos and 0.6cm3 Cylin-
drical Chamber, at the location of the eye lens (76 cm from central axis),
with 10 cm x 10 cm field size. . . . . . . . . . . . . . . . . . . . . . . 99
6.4 MU and Dose to the Eye Lens . . . . . . . . . . . . . . . . . . . . . . 100
6.5 MU and Dose to the Chest . . . . . . . . . . . . . . . . . . . . . . . . 101
List of Tables
2.1 Summary of dosimeters in terms of size, sensitivity, accuracy, and im-
portant applications . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
3.1 Estimated combined Type A and Type B uncertainty to (1σ) for dose
profile, depth-dose and anthropomorphic phantom VMAT measurements
using an ionisation chamber. . . . . . . . . . . . . . . . . . . . . . . . 48
4.1 Quantification of couch scatter. Average difference = 0.8% . . . . . . . 55
6.1 MU and dose per fraction delivered to the eye lens for three separate
patient plans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
6.2 MU and dose per fraction delivered to the chest for three separate patient
plans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
6.3 VMAT Results (70 Gy, 35 fractions) . . . . . . . . . . . . . . . . . . . 100
xvi
List of Abbreviations
3DCRT Three-Dimensional Conformal Radiation Therapy
AAPM American Association of Physicists in Medicine
CIED Cardiac Implantable Electronic Device
EBRT External Beam Radiation Therapy
FSD Focus to Source Distance
ICD Implantable Cardiac Defibrillator
ICRP International Commission on Radiological Protection
IMRT Intensity Modulated Radiation Therapy
MLC Multi-Leaf Collimator
MU Monitor Unit
OAR Organ at Risk
PDD Percentage Depth Dose
PTV Planning Target Volume
SSD Source-to-Surface Distance




Cancer is defined as the uncontrolled malignant growth of a group of cells caused by a
series of changes in the genome. This disease is one of the leading cause of deaths in
Australia. In 2014, cancer was the second most common cause of death in Australia, ac-
counting for approximately 3 of every 10 deaths [4]. In 2013, there were 44,108 deaths
from cancer in Australia of these deaths, 24,972 were male and 19,136 female [5]. This
placed cancer fourth to the leading rates of mortality amongst patients in Australia.
Globally, more than one in three people will develop cancer during their lifetime and
about one in four will die from the disease [6].
According to the Australian Institute of Health and Welfare (AIHW), cancer mortality
amongst the Australian population is decreasing, however, cancer incidence rates are
steadily increasing. The report, Cancer mortality trends and projections: 2014-2025 [7]
showed that in 2012, a total of 122,093 new cases of cancer were diagnosed in Australia,
at a rate of 485 new cancer cases per 100,000 persons. A recent report by AIHW, Cancer
in Australia 2017 [5] stated that the number of new cases expected to be diagnosed in
2017 is estimated to be 134,000 (excluding basal and squamous cell carcinoma of the
skin, as these cancers are not notifiable diseases and hence are not reported to cancer
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registries). This increasing trend is attributed to Australias aging population, improved
diagnostic technology in the ability to diagnose smaller volume tumours and increased
public awareness of cancer prevalence. A combination of these has led to more patients
presenting for diagnosis. The report predicted that this number is estimated to increase
with age, with additional diagnoses per year.
Prostate cancer is the most commonly diagnosed cancer in males in Australia and the
third most common cause of cancer death. It is more common in older men, with 63% of
cases diagnosed in men over 65 years of age [8]. In 2013, 19,233 new cases of prostate
cancer were diagnosed in Australia. This represented 30% of all cancers diagnosed in
Australian men. The risk of being diagnosed with prostate cancer by the age of 85 is 1
in 5 men [8]. In 2013, there were 3,112 deaths caused by prostate cancer, accounting
for 13% of all cancer deaths in Australian men [8].
Treatment options for prostate cancer include surgery, chemotherapy, hormone ther-
apy, radiation therapy, or a combination of these. Radiation therapy includes options
such as high or low dose rate (HDR or LDR) brachytherapy, or external beam options
such as 3D conformal radiation therapy (3DCRT), intensity modulated radiation ther-
apy (IMRT), volumetric modulated arc therapy (VMAT) and Helical TomoTherapy R©
techniques. The types of radiation therapy of concern in this study is external beam
radiation therapy.
The principle goal of radiation therapy is to maximise the dose delivered to a well-
defined treatment volume, while minimising the dose to surrounding healthy tissues and
organs, with the aim of eradicating the disease, prolonging the life and/or improvement
of the quality of life of the patient. However, external beam radiation therapy also brings
an unavoidable out-of-field dose to the patient. Although it may be relatively small, it
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could cause a significant radiobiological effect to the critical organs/tissues such as the
eye lens and heart outside the treatment site. Arising from the components within the
accelerator, head leakage and collimator scatter are predominantly the main sources of
external radiation which result in the out-of-field dose deposition in the patient. It is of
great importance to accurately predict and estimate the out-of-field doses for the treat-
ment planning.
Intensity Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc Ther-
apy (VMAT) have become extremely popular in radiotherapy. This popularity has gen-
erated the attention to determine the out-of-field radiation dose as opposed to conven-
tional therapy, since the dose has significantly been amplified due to the increased num-
ber of monitor units needed for IMRT and VMAT treatments.
From the epidemiological studies on Chernobyl clean-up workers, interventional radiol-
ogy and cardiology physicians and bomb survivors eye lens doses have received a lot of
attention as some showed that the threshold dose for cataract induction could be lower
than the assumed value of 8 Gy. This resulted in the need for a detailed re-evaluation of
the eye lens radio-sensitivity and an associated reliable dose assessment. For this rea-
son, the International Commission on Radiological Protection ICRP 2011 [1] reviewed
epidemiological evidence for the late effects of radiation induced damage. The ICRP
2011 then issued a Statement on Tissue Reaction containing a series of recommenda-
tions including a revision of the eye lens limit that lowers the threshold for eye lens
opacities from the previous 8 Gy to 0.5 Gy [1].
EviQ Cancer Treatments Online [3] have also made their own recommendations on
action thresholds for Cardiac Implantable Electronic Devices (CIEDs). Their recom-
mendation includes a revision of the CIED limit which suggests that the risk of device
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failure is low if the total dose to the device is less than 2 Gy and it may be appropriate
to accept a total dose of 2-10 Gy to the device. There is a significant risk that CIEDs
malfunction due to neutrons generated by x-ray beams of energies 10 MV or greater.
Therefore, if the device is likely to receive a dose of >10 Gy then the risk of failure is
significant and replanning of the treatment should be performed to reduce the dose to
the CIED [3].
To develop an accurate and comprehensive out-of-field risk model for cancer patients,
there are many challenges involved. Currently there are a few options available to de-
termine the out-of-field dose which includes measuring the dose to the patient. These
measurements are time consuming and yield only the dose to the specific measured
points. They are specific to the particular treatment and patient examined. Most treat-
ment planning systems do not accurately model photon or electron leakage/scatter from
the LINAC head. Alternatively, estimates of the dose have been made by the AAPM
Task Group 36 report on fetal doses [9]. The estimates are unfortunately associated with
large uncertainties. Thus, a more thorough study is needed to establish the out-of-field
dose from radiotherapy treatments. This study aims to develop a better understanding
of components of out-of-field dose and make an accurate determination of the doses to
the sensitive cells of the eye lens and for patients with CIEDs (including pacemakers
and ICDs), for patients undergoing VMAT of the prostate.
1.1 Research Scope and Aims of this Thesis
The research scope of this project addresses the underestimation of the treatment plan-
ning systems in determining out-of-field dose. The aims of this thesis are divided into
the following objectives:
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• Develop a better understanding of the contributing factors that result in dose to
the eye lens and chest region (for patients with CIEDs) during prostate treatment.
• Develop a method of measuring the individual out-of-field dose components (pa-
tient scatter, collimator scatter and head leakage) in a phantom.
• Make an evaluation of the doses to the eye lens and chest region (for patients with
CIEDs) for patients undergoing VMAT of the prostate at St George Hospital and
determine if these doses are within the ICRP and EviQ limits.
1.2 Thesis Structure
This thesis consists of 7 chapters that will endeavour to accomplish the aforementioned
project aims and the specific objectives.
Following this introduction, Chapter 2 aims to provide a background into the out-of-
field dose in External Beam Radiotherapy, specifically for the treatment of prostate can-
cer. It focuses on the importance of minimising the out-of-field dose to the sensitive
cells of the eye lens and CIEDs in the chest region and reviews past approaches to mea-
suring out-of-field dose found in the literature for different treatment options.
Chapter 3 begins by distinguishing the experimental principles associated with the use
of ionisation chambers in measurements. A detailed uncertainty analysis is completed
to account for the type A and type B uncertainties in the upcoming experiments.
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Chapter 4 investigates the depth-dose measurements of out-of-field dose measured with
a Roos chamber. It begins by examining the quantification of the couch scatter and
looks at increasing the depth of measurement for different field sizes.
Chapter 5 outlines the characterisation of the out-of-field dose components and looks at
the relative contributions of each of the sources. It begins by dose profile measurements
and continues with depth-dose measurements at different combinations of collimator
angle, field size and depth inside a PTW motorised water tank.
Chapter 6 reveals out-of-field doses for clinical VMAT treatments in patients under-
going VMAT of the prostate. A method of calculating the dose given to patients who
undergo treatment was established for measuring the dose to the sensitive region of the
eye lens and CIEDs on the chest.
Chapter 7 concludes this thesis by providing a summary of the overall outcomes and
provides recommendations for future research in out-of-field dose.
Chapter 2
Literature Review
This chapter aims to provide a background into the out-of-field dose for External Beam
Radiotherapy, specifically for the treatment of prostate cancer. It starts with an overview
of the common treatment options available for prostate therapy. It then examines the
major sources of out-of-field dose and the importance of minimising this dose to the
sensitive cells of the eye lens and to the chest for patients with CIEDs (including pace-
makers and ICDs). Moreover, it reviews the current and past proposed approaches to
measuring out-of-field dose found in the literature for different treatment options.
2.1 Prostate Cancer and Treatment Options
The prostate gland is an organ that is made up of glandular, fibrous, and muscular ele-
ments, and is an important part of the male reproductive system. Located immediately
below the bladder, the prostate is situated in front of the bowel, encapsulating the ure-
thra. Its foremost function is to secrete fluids that protect and augment sperm. A healthy
prostate is approximately the dimensions of a walnut.
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Prostate cancer is a disease where the cells in the prostate gland become abnormal and
grow uncontrollably to form tumours. Cancerous cells in the prostate are not lethal
on their own, however, they are capable of metastasising; spreading to other parts of
the body via the blood or lymph system creating new tumours. Benign tumours do
not spread, although they may interfere with adjoining organs and constituents, causing
problems or discomfort. The causes of prostate cancer are not clearly known, however
it is known that age is an important factor. It is estimated that by the age of 85, 1 in 5
Australian males will be diagnosed with prostate cancer.
Patients with localised prostate cancer have the following options for management, de-
pending on the severity of their case. For low severity patients, no initial treatment can
be recommended with active surveillance typically performed by a general practitioner
(GP). Patients with carcinoma of the prostate can be given the option of the surgical
removal of the entire prostate, better known as radical prostatectomy (nerve-sparing
surgical procedure). In general, surgery is an option if the tumour is confined to the
prostate gland with no extension through the capsule or into the seminal vesicles.
Patients may also be administered chemotherapy for the systemic treatment of cancer.
It can be delivered via injection (intravenous, intra-arterial or intrathecal), orally, or for
some types of cancer, by cavity insertion. Hormone therapy (androgen deprivation ther-
apy) is another treatment option which involves the use of hormones such as leutinising
hormone-releasing agonist or antagonist to reduce the production of testosterone. It is
rarely used as a monotherapy for prostate cancer due to its ineffectiveness on its own,
but rather as an adjuvant therapy to radical prostatectomy or radiation therapy, to shrink
the target.
Another modality recommended for the treatment of prostate cancer is radiation ther-
Literature Review 9
apy. Radiation therapy of the prostate includes options such as high or low dose rate
(HDR or LDR) brachytherapy which can be delivered internally, or external beam
(EBRT) options such as 3D conformal radiation therapy (3DCRT), intensity modu-
lated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT) and Helical
TomoTherapy R©. The selection of a particular procedure or a combination of procedures
depends on the established prognostic factors such as stage, grade and pre-treatment
prostate specific antigen (PSA) concentration, as well as the availability of such treat-
ments.There is no single effective treatment of prostate cancer as the best treatment
option is often highly patient specific.
2.2 Brachytherapy
Brachytherapy to the prostate is an invasive procedure involving sealed radioactive
sources being inserted inside or adjacent to the region requiring treatment. This type
of radiation aims to achieve highly localised dose distributions to spare normal tissue
whilst treating the tumour. With this mode of therapy, a high radiation dose can be
delivered locally to the tumour with a rapid dose fall-off in the surrounding normal tis-
sue. Prostate brachytherapy is an interstitial form of therapy. Brachytherapy radiation
sources are introduced via catheters, needles or applicators placed within the treatment
region. Brachytherapy implants are used for early stage cancers, either alone or in con-
junction with external beam radiation therapy.
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2.3 External Beam Radiation Therapy
EBRT is a non-invasive treatment that uses high energy x-rays (usually 6-18 MV) to
deliver dose to the patient, most commonly with a linear accelerator. Previously, a four-
field box technique was used to deliver treatment to the prostate, seminal vesicles and
lymph nodes, with generally 45 Gy prescribed to the whole treatment field, and the
prostate itself boosted to 70 Gy or more. Commonly today Three-Dimensional Con-
formal Radiation Therapy (3D-CRT), Intensity Modulated Radiation Therapy (IMRT),
Volumetric modulated arc therapy (VMAT) and TomoTherapy R© are the techniques
used.
Three-Dimensional Conformal Radiation Therapy (3D-CRT) has been commonly used
in the past since it uses Multi-Leaf Collimators (MLCs) to conform or shape the pre-
scription dose volume of the prostate and other affected areas to the PTV, while at the
same time keeping the dose to specified organs at risk below their tolerance dose. 3D-
CRT is based on 3D target localisation, 3D treatment planning, and 3D dose deliv-
ery techniques. Target localisation is accomplished through anatomical and functional
imaging: CT, MRI, single photon emission computed tomography (SPECT), PET and
ultrasound. Treatment planning is accomplished either with standard forward planning
techniques, which configure uniform intensity beams shaped to the geometrical projec-
tion of the target or for further developed conformal radiotherapy techniques with in-
verse planning, which in addition to beam shaping, utilises intensity modulated beams
to enhance target dose homogeneity and spare organs at risk. Dose delivery techniques
range from the use of standard regular and uniform coplanar beams to intensity modu-
lated non-coplanar beams created with MLCs.
The concept of 3D conformal dose distribution has a major limitation which involves
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limited knowledge on the extent of the tumour. Despite the modern advances in imaging,
the clinical target volume (CTV) is often not fully discernible and imaging techniques
do not reveal the CTV. Due to the invasive capacity of the disease, only the gross tu-
mour volume (GTV) is imaged, which may result in the entire tumour being missed or
underdosed [10]. Hence, 3D-CRT is not a new modality of treatment and is not proven
to be better than other well-tested forms of conventional radiation therapy.
IMRT is an advanced form of 3D-CRT which involves the treatment of the patient from
a number of different directions. This is the same as 3D-CRT, which is also delivered
from multiple angles and is optimised to deliver a high dose to the target volume and
acceptably low dose to the surrounding normal structures. IMRT treatments generally
deliver doses of 2-2.5 Gy per fraction, for a total of 75-85 Gy over 30-36 days [11].
Most Australian men with localised prostate cancer receive conventionally fractionated
treatment. This treatment consists of 1.8-2 Gy per fraction, for a total of 74 Gy in 37
fractions [12].
IMRT treatments are delivered in static or dynamic mode. Static IMRT often referred
to as the step and shoot mode, where the intensity modulated fields are delivered with
a sequence of small segments or subfields, each subfield with a uniform intensity. This
is where the beam is only turned on when the MLC leaves are stationary in each of
the prescribed subfield positions during dose delivery. Dynamic IMRT is often referred
to as the sliding window mode, where the intensity modulated fields are delivered in a
dynamic manner with the MLC leaves moving during delivery. For a fixed gantry posi-
tion, the opening shaped by each pair of opposing MLC leaves is swept across the target
volume under computer control with the radiation beam turned on to create the desired
fluence map.
Furthermore, IMRT has been shown to have a steep dose gradient outside target bound-
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aries. This steep gradient has a great advantage near the edge of the treatment field,
however, far from the treatment field, this advantage is lost. This is due to the fact that
near the treatment field IMRT can provide a more conformal treatment, which decreases
the volume of tissue receiving high doses. However, far from the treatment field, with
the presence of modulation, a higher amount of monitor units and greater beam on time
leads to increased head leakage and therefore higher doses farther from the treatment
field [13] compared to 3D conformal treatments.
TomoTherapy R© is an alternative option used to deliver EBRT. TomoTherapy R© involves
the use of multiple rotations of a narrow fan beam with a continually changing one-
dimensional profile delivering dose to the patient. The process of dose delivery involves
multiple binary MLCs (i.e. either in the open or closed state operating in the supe-
rior/inferior direction of the patient) forming a one-dimensional profile that constantly
changes. Combining the one-dimensional profile with the beam rotation, intensity mod-
ulation in two dimensions is produced. The patient is also transported through the field
as the beam is rotated, leading to a helical delivery. The combination of the one di-
mensional profile and the helical delivery leads to the two dimensions. TomoTherapy R©
can deliver treatment with a sequence of rotational modulated beams (known as serial
TomoTherapy R©), with each rotation at a fixed couch position or as a beam following
a helical trajectory relative to the patient. Furthermore, advantages of TomoTherapy R©
include its proficiency in generating very complex, high intensity modulated dose dis-
tributions due to its greater number of degrees of freedom and that it has the ability to
treat large volumes in a single treatment delivery.
Volumetric modulated arc therapy (VMAT), another option for EBRT, it is a unique
form of IMRT optimisation that allows the radiation dose to be delivered in more than
one rotation of up to 360 degrees, using either a constant dose rate or variable dose rate
Literature Review 13
during rotation. This technique is similar to TomoTherapy R© in that a full 360 rotation of
beam directions are available, however, it is fundamentally different in that the dose is
delivered to the entire planning target volume (PTV) in a single source rotation and the
patient is static. The modulated field in VMAT is achieved by varying dose rate, MLC
aperture and orientation, and gantry angle, with the beam, switched on continuously for
efficient treatment.
A study by Palma et al. (2008) [14] discussed the use of VMAT in comparison with
IMRT and 3D-CRT for the treatment of prostate cancer. VMAT, IMRT, and 3D-CRT
plans were created for 10 computed tomography data sets. The parameters evaluated
were dose to organs at risk, equivalent uniform doses, dose homogeneity and conformity
and monitor units required for delivery of 2 Gy per fraction. Both IMRT and VMAT
techniques resulted in lower doses to normal critical structures than 3D-CRT. The low-
est dose to organs at risk and most favourably equivalent uniform doses were achieved
with VMAT which was significantly better than IMRT. The VMAT plans required fewer
monitor units than IMRT and 3D-CRT [14]. Fewer monitor units are particularly ad-
vantageous in reducing the out-of-field, scattered and leakage doses.
A study by Wolff et al. (2009) [15] compared VMAT to serial TomoTherapy R©, step-
and-shoot IMRT and 3D-CRT for treatment of prostate cancer. Based on CT datasets of
9 patients treated for prostate cancer step-and-shoot IMRT, serial tomography (MIMiC),
3D-CRT and VMAT were compared in regards to plan quality and treatment efficiency.
All the approaches showed improved quality when compared to 3D-CRT treatments,
with serial Tomotherapy R©, providing the best OAR sparing and VMAT being the most
efficient treatment option in the comparison, reducing treatment time to 1.8-3.7 minutes
and MU to <400 MU for a 2 Gy fraction [15].
Literature Review 14
A study by Tsai et al. (2011) [16] compared step-and-shoot IMRT, helical TomoTherapy R©,
and VMAT, in terms of treatment and dosimetry for prostate cancer. Three plans for
each treatment delivery method were completed for twelve patients. The study found
that the mean required MUs were 309.7 for VMAT, 336.1 for step-and-shoot and 3368
for TomoTherapy R©. The advantage of lower MUs is a less scattered dose to the body.
The treatment time required was lowest for VMAT at 2.6 minutes, with step-and-shoot
IMRT and TomoTherapy R© taking 3.8 minutes [16]. Less treatment time is advantageous
in terms of potentially reducing intrafractional movement [17] and reducing out-of-field,
scattered and leakage doses [18]. Although Helical TomoTherapy R© can have treatment
times longer than treatment times using a conventional linear accelerator. When com-
paring to RapidArc (Varians implementation of VMAT), a typical prostate treatment
time using TomoTherapy R© requires a treatment time of 4-7 minutes, whereas RapidArc
takes only 1.5 minutes. This treatment time is only for simple cases [19,20]. Despite the
longer treatment times, the greater amount of shielding involved in the TomoTherapy R©
system minimises radiation leakage that could be detrimental to patients [18].
Another study by Davidson et al. (2011) [21] assessed the role of VMAT relative to
IMRT and Helical TomoTherapy R© in the management of localised, locally advanced
and post-operative prostate cancer. Twenty-five prostate cancer patients were selected
for this study to quantify the differences in treatment delivery and dosimetry between
the various treatment modalities. This study showed that VMAT provided the most im-
provement in efficiency of delivery resulting in reduction in treatment times over IMRT
and Helical TomoTherapy R©. VMAT also required much fewer monitor units than IMRT
over all treatment volumes, with the reduction per fraction ranging from 100-423 MU
from the smallest to largest volumes [21]. The study clearly demonstrated that VMAT
offers the potential to deliver treatment plans of equal quality with more efficiency and
fewer MUs than IMRT or Helical TomoTherapy R© in all simple and complex volumes
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involved in prostate cancer radiotherapy.
Overall, for prostate treatments, the number of MUs have been reported to be 16-
39% lower for VMAT than for step-and-shoot IMRT [15,21,22]and 42-68% lower than
for sliding window IMRT [14, 22, 23]. For single arc therapy, the leakage radiation is
lower, hence the out-of-field doses are slightly lower for VMAT than for step-and-shoot
IMRT [22]as shown in Figure 2.2. Near the treatment field, where internal patient scat-
ter dominates, there is no difference between VMAT and other IMRT modalities.
Conclusively, VMAT has been reported to deliver similar dose distributions to IMRT
while using fewer monitor units (MUs). When scatter and leakage are the major con-
tributors to dose at points outside of the field edge, VMAT has the potential to reduce
out-of-field doses by using fewer MUs. Most standards require that the linac head leak-
age dose be less than 0.1% of the useful (primary) beam dose [24]. However, the mag-
nitude of the combined scatter and leakage dose varies with beam energy, field size and
the distance from the field edge, and therefore, accurate estimation of out-of-field dose
requires measurements and calculations performed under clinically realistic conditions.
The photon dose equivalent as a function of distance from central axis for 6 MV and
10 MV beam on a Varian and Siemens delivery system for IMRT treatment of prostate
is shown in Figure 2.1 [25]. Dose as a function of distance from central axis for 6 MV
beam delivery on a Siemens delivery system for IMRT and VMAT treatment of the
prostate is shown in Figure 2.2 [22]. In Figure 2.1, close to the field edge, there is mini-
mal difference in out-of-field dose for 6 MV and 10 MV IMRT treatment. In Figure 2.2,
close to the field edge there is no difference in out-of-field dose for IMRT and VMAT
treatments. For both Figures 2.1 and 2.2, further away from the field edge at distances
greater than 20 cm the out-of-field dose increases and this becomes of great concern.
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Figure 2.1 Photon Dose Equivalent as a function of Distance from Central Axis for IMRT of the
prostate Kry et al. (2005b) [25].
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Figure 2.2 Dose as a function of Distance from Central Axis for IMRT and VMAT of the prostate
Blais et al. (2012) [22]
2.4 Linear Accelerators
A linear accelerator (LINAC) is currently the most standard device used for external
beam radiation treatments for patients with cancer. A clinical linear accelerator uses
high frequency electromagnetic waves to accelerate electrons to high energies, generat-
ing photons. A typical modern high energy LINAC can provide 6, 10 and 18 MV photon
energies and 6, 9, 12, 16 and 22 MeV electron energies. Some linear accelerators pro-
vide x-rays only in the low mega-voltage range (4 or 6 MV), while others provide both
x-rays and electrons at various megavoltage energies. For the treatment of superficial
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tumours a high-energy electron beam is used. For the treatment of deep-seated tumours
the high-energy electron beam can be made to strike a target to produce high energy
x-rays with penetrating characteristics.
Within a LINAC electrons are accelerated linearly in an accelerating waveguide to a
high velocity using energy from high-power microwaves which are delivered to the ac-
celerating structure in the form of short duration pulses (5 microseconds duration) from
the klystron or magnetron through a transmission microwave waveguide. An electron
gun injects low-energy electrons at one end of the accelerating waveguide. The elec-
trons are accelerated along the guide to speeds approaching the speed of light. The
electrons then enter a bending magnet assembly whereby they are redirected toward
the centre of the beams gantry axis of rotation known as isocentre. When the LINAC
is operated in x-ray mode, the electron beam hits a target and x-rays are produced by
the bremsstrahlung production process. When the LINAC is used in electron mode,
the electrons are made to strike a scattering foil prior to exiting the LINAC. A detailed
schematic showing the LINAC waveguide and beam path with beam monitoring and
collimation systems is shown in Figure 2.3. Figure 2.3 shows the main components of
the LINAC that are housed in the gantry. Also shown are the connections and relation-
ships among the various LINAC components.
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Figure 2.3 Schematic drawing of the internal components of a medical linear accelerator,
adapted from [24].
2.4.1 Linear Accelerator Head
A LINAC treatment head contains numerous mechanisms that influence the production,
shaping, confining and monitoring of the clinical photon and electron beams. Electrons
originating in the electron gun are accelerated in the accelerating waveguide to the de-
sired kinetic energy to be transported, in the form of a pencil beam, through the beam
transport system into the LINAC treatment head, where the clinical photon and electron
beams are produced [24].
The major components found in a typical LINAC include: several retractable x-ray
targets, primary collimators, flattening filters and electron scattering foils (also called
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scattering filters), dual transmission ionisation chambers, adjustable secondary collima-
tors (upper and lower jaws), a field defining light with a range finder and multi-leaf
collimators (MLCs).
A clinical photon beam is accomplished with three collimator devices: a primary colli-
mator, secondary movable beam defining collimators (upper and lower jaws) and multi-
leaf collimators (MLCs). In expansion to the primary and secondary collimators, clini-
cal electron beams require electron beam applicators (cones) for beam collimation.
The primary collimator characterises the largest available round field size and is a con-
ical opening machined into a tungsten protecting block, with the sides of the conical
opening projecting on to edges of the target on one side of the block and on to the flatten-
ing filter on the opposite end. The thickness of the protecting block is typically intended
to attenuate the average primary x-ray beam intensity to under 0.1% of the underly-
ing value (three tenth-value layers (TVLs)). As per the International Electro-technical
Commission (IEC) suggestions, the maximum leakage should not surpass 0.2% of the
open beam value [24].
The secondary beam defining collimators are made of four blocks, two shaping the
upper and two shaping the lower jaws of the collimator. The secondary collimators are
able to provide rectangular or square field sizes of up to 40 cm x 40 cm, at the linac
isocentre. Modern LINACs can also include independent (asymmetric) jaws that are
able to provide asymmetric fields [24].
Multi-Leaf Collimator (MLCs) provide additional conformal shaping of the radiother-
apy treatment beams. Using an MLC, the fluence profile of the beam is modulated
through the use of multiple smaller segments or by the use of a sliding window, whereby
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the MLC leaves move across the portal in an ever changing sequence, irradiating only a
portion of the field at any moment in time. The number of MLCs in commercial LINAC
machines is approximately 120 leaves (60 pairs) covering fields sizes of up to 40 cm x
40 cm and requiring 120 individually computer controlled motors and control circuits.
Since the introduction of MLCs, they have become invaluable in supplying intensity
modulated fields in IMRT and/or VMAT [24].
Therefore, treatments that involve a linear accelerator use multiple mechanisms that in-
fluence the shaping, confining and monitoring of the clinical photon and electron beams,
with heterogeneous fluence profiles to produce complex isodose distributions, improve
target coverage and simultaneously avoid organs at risk.
2.5 Sources and Characteristics of Out-of-Field Dose
The longer beam-on times and longer monitor units required for IMRT and VMAT
treatments results in three unintended sources of radiation (2.4):
1. Patient scatter, scatter of the primary treatment beam outside the treatment area
once it has entered the patient;
2. Collimator scatter, scatter of radiation in the head of the accelerator, which exits
the accelerator through the treatment field opening but strikes the patient outside
the treatment field; and
3. Head leakage, radiation that penetrates through the accelerator head shielding and
strikes the patient away from the treatment field [13].
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Figure 2.4 Sources of out-of-field dose from a medical linear accelerator: (1) patient scatter, (2)
secondary collimator scatter; and (3) head leakage.
The total dose outside the treatment field is affected by the distance from the field edge.
In an IMRT treatment, the fall-off in dose considerably depends on the objectives and
quality of the treatment plan [13]. The dose outside the treatment field also depends
on field size, increasing with increasing field size as larger irradiated volumes produce
more patient scatter. This field-size dependence is most pronounced close to the field
edge, where patient scattered radiation is the most important component of the out-of-
field dose. Away from the field edge, there is no field size dependence.
For modulated treatments, the dose outside the treatment field also depends on beam
modulation. The dose increases with increasing modulation as more head leakage is
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generated as the number of monitor units (MU) increases to deliver the modulated fields.
Beyond 20 cm from the field edge, head leakage radiation that penetrates through the
accelerator head shielding and collimator scatter radiation in the head of the accelerator,
which exits the accelerator through the treatment field opening and strikes the patient
outside the treatment field, becomes the most important component of the out-of-field
dose. The dose modulation dependence is the most noticeable, away from the field
edge, whereas very near the field edge there is no modulation dependence. Differences
among accelerator head models as a result of variations in head shielding designs and
beam energy spectra can also cause out-of-field dose to differ slightly.
In contrast, out-of-field dose varies minimally with depth in the patient, however, there
is an exception to this depth independence near the surface of the patient. The dose at
the surface is highly elevated by electrons from the accelerator head; this dose elevation
is maximal at the surface and decreases with depth until dmax and then remains rela-
tively constant at all depths below that [26].
Therefore, patient scatter has been reported to be the dominant source of radiation dose
outside the field for approximately 0-10 cm from the field edge and at distances greater
than 20 cm, head leakage and collimator scatter radiation dominates [13]. Due to the
contributions of patient and collimator scatter, the energy spectrum is softer outside the
treatment field than within. This means that the mean energy inside the treatment field
at dmax for a 6 MV photon beam is approximately 1.6 MeV (for a Varian accelerator)
and the average energy of the photon spectrum outside of the treatment field is typically
between 0.2 and 0.6 MeV [27].
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2.5.1 MLC and Collimator Orientation
Leakage through the MLCs consists of transmission through the leaves and leakage be-
tween the leaves. The presence of MLCs offers additional head shielding to the LINAC
and reduces the overall head leakage and collimator scatter reaching the patient. With
Varian LINACs the presence of MLCs has the potential to reduce the out-of-field dose
by strategically orienting their location. If the MLC leaves open along the axis of the
patient (as opposed to across the patient axis), the leaves continue to shield the patient,
reducing the dose by 6% to >50% depending on the distance from field edge [26]. In
order to reduce out-of-field dose, jaws and MLCs should be as close as possible. This
is not feasible with the treatment of patients as the orientation of jaws and MLCs varies
with differing treatment sites.
2.6 Critical Out-of-Field Regions in Prostate Radiation
Therapy
2.6.1 Eye Lens: Cataracts
Cataracts lead to the loss of transparency of the eye lens, which can progress slowly to
cause vision loss and may eventually lead to blindness. Cataracts are the most common
eye disease and the most common cause of visual impairment in the world. A report
by AIHW, Cataracts in nearly one third of older Australians [28] stated that in 2004,
almost 1.5 million Australians aged 55 or over suffered from untreated cataracts, which
represents 31% of that population. Age-specific rates for cataracts increase with age for
both men and women and are over 70% for men and women aged 80 or more. Preva-
lence rates are higher amongst women than men [28].
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Within years after the discovery of X-rays, severe adverse effects to the eye from ra-
diation were reported and cataract formation was seen to be one of the earliest effects
observed among atomic bomb survivors. The subcapsular lens epithelium, particularly
where it differentiates to lens fibres, is highly susceptible to radiation damage. The de-
velopment of radiation-induced cataracts is dependent on radiation dose, dose rate and
age of the lens, and is a known late effect from radiation therapy [29]. As a result of
epidemiological studies on Chernobyl clean-up workers, interventional radiology and
atomic bomb survivors [29,30], the threshold for cataract induction was suggested to be
lower than previously assumed. As a result, the need for a detailed re-evaluation of the
eye lens radiosensitivity and an associated reliable dose assessment was essential. The
Statement on Tissue Reaction was released by the ICRP, which pertained to the accept-
able recommendation for the revision of the eye lens limit, lowered the annual limit of
radiation dose from 150 mSv to 20 mSv [1].
In a recent study by Behrens et al. (2009) [2], the depth of the sensitive region of the eye
lens was found to be between 2.8 mm and 3.8 mm, with a mean value of 3.4 mm [2].
This means that since the sensitive region of the eye lens where radiation becomes of
critical concern is between 2.8-3.8 mm, low penetrating radiation such as electrons are
able to deposit dose resulting in a risk of developing a cataract [2]. A detailed diagram
of the eye lens, particularly the radio-sensitive region, is illustrated in Figure 2.5.
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Figure 2.5 Diagram of the eye representing the radio-sensitive region of the lens.
2.6.2 Chest: Cardiac Implantable Electronic Devices (CIEDs) such
as: Pacemakers and Implantable Cardiac Defibrillators (ICDs)
Cardiac Implantable Electronic Devices (CIEDs), such as pacemakers and implantable
cardiac defibrillators (ICDs), are implanted subcutaneously overlying the pectoral mus-
cles or occasionally implanted in the abdominal wall of patients with arrhythmia. CIEDs
are located at depths of 5-30 mm below the skin surface [31, 32]. A pacemaker helps
control abnormal heart rhythms using electrical pulses to prompt the heart to beat at
a normal rate. An ICD monitors heart rhythms of patients who are at risk of sudden
cardiac arrest (SCA) and is designed to deliver an electrical shock to the heart when
the heart rate becomes dangerously fast, or fibrillates. The ICD can be programmed to
provide therapy when required. Most new ICDs can now act as both a pacemaker and
defibrillator.
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Cardiac Implantable Electronic Devices (CIEDs) are sensitive to relatively low levels of
radiation, as documented in AAPM Report TG-34 [33] and EviQ guidelines [3]. Pace-
makers and ICDs may be affected by radiotherapy to the lung, breast, chest wall, head
and neck, skin and for lymphomas. Implantable electronic devices, if exposed to exces-
sive cumulative doses, can malfunction as a result of a build-up of electrical charge and
for this reason, it is imperative to be aware of the dose assessment to these devices. Dose
malfunctions can also occur from other mechanisms, such as dose rate effects (which
have a complicated mechanism but have been observed at very low doses) [34].
There is a significant risk that CIEDs malfunction due to neutrons generated by x-ray
beams of energies 10 MV or greater. Such neutrons have been documented to cause
CIED malfunction when the device was 1.4 meters from the beam edge. The increased
risk of using high energy photon beams applies to the treatment of any part of the body.
Some earlier studies in the literature used >10 MV beams to estimate the dose sensitiv-
ity of CIEDs and may have overestimated the effect of dose due to unrecognised neutron
effects [3].
There are no universal guidelines specifying radiation dose limits to cardiac implantable
electronic devices (CIEDs) such as pacemakers and ICDs sensitive to ionising radiation.
Although it is widely accepted that accumulatively doses above 2 Gy for pacemakers
and 1 Gy for ICDs should be avoided and they should not be placed in the direct path
of the radiation beam. Damage caused by neutrons is much greater than that caused
by photons. Unwanted neutron contamination is only produced for photon beam ener-
gies greater than 10 MV. Therefore, considerable published observational (in-vivo) data
suggests that the majority of radiation therapy associated CIED malfunctions are due to
neutron exposure (from photons ≥10 MV) [35]. There is uncertainty in the safe levels
of radiation exposure for CIEDs, however since the release of the 2017 HRS Interna-
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tional expert consensus statement, the risk of failure of the device is low, as there is no
evidence of damage up to 5 Gy [35]. It is also recommended that patients with CIEDs
be treated with photon beams of 10 MV or lower to avoid the risk of malfunction. Out-
of-field doses measured for prostate patients to the chest will be well under this limit
unless the device is within a few centimeters of the field edge.
2.7 Dosimeters for Out-of-Field Dose Measurements
2.7.1 Solid State Dosimeters
Common types of radiation detectors used in dosimetry are diode, diamond, MOSFET,
TLD, ionisation chambers and radiochromic film. The measurement of dose outside the
treatment field poses many unique challenges. Due to the radiation field being different
from inside the treatment field, the dose outside the treatment field is difficult to detect
as signals for most detectors are extremely low. On the basis of that, specific impli-
cations of the size, sensitivity, accuracy, cost, and workload need to be considered for
each separate dosimeter before being selected as suitable for out-of-field measurements.
An ideal radiation dosimeter for out-of-field dose measurements would be able to detect
such low signals with stability. Ideally, a radiation dosimeter would have a number of
favourable features such as being stable, linear with dose, linear with dose rate, energy
independent, independent of radiation type, direction independent, have direct read-out
capabilities and require minimal correction.
Diode detectors allow for real-time readout, have small sensitive volumes, high spatial
resolution and are mechanically rugged such that handling will not influence its high
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sensitivity. A disadvantage that makes diodes unsuitable for out-of-field measurements
is their energy dependence at low energies. Diodes show variation in dose response with
temperature, dependence of signal on the dose rate, angular dependence, and energy de-
pendence [24].
Diamond detectors are solid-state detectors with a small sensitive volume (<0.01 cc).
Diamond detectors have a low atomic number (Z = 6) which is close to the effective
atomic number of water (Zeff = 7.4), as a result they have negligible energy depen-
dence and are useful across a wide range of field sizes. A study by Rodriguez et al.
(2007) [36] measured the current of a diamond detector in air at 100 cm from a Co-60
source in a 10 cm x 10 cm field to be 5.5 nA at a bias voltage of 150 V. On the other
hand, with the same setup, the current measured with an ionisation chamber was found
to be 0.39 nA at a bias voltage of -300 V. This study showed that the sensitivity of a
diamond detector is higher than an ionisation chamber [36]. The main drawbacks of di-
amond detectors is their lack of immediate availability, to their manufacturing difficulty
and higher cost compared to ionisation chambers and diodes.
The Metal oxide silicon semiconductor field effect transistor (MOSFET) detector is
a miniature silicon transistor. MOSFETs are capable of real-time measurements, pos-
sess high spatial resolution, small in size and are based on the measurement of the
threshold voltage, which is a linear function of absorbed dose. Ionising radiation pen-
etrating the oxide generates charge that is permanently trapped, thus causing a change
in threshold voltage (an electrical characteristic of the device). The integrated dose may
be measured during or after irradiation. MOSFETs have a limited lifespan. They can
be exposed with no applied voltage and can be implanted interstitially. MOSFETs have
been previously used for out-of-field measurements by Wang and Xu (2008) [37], their
advantages include its small size, immediate readout, ease of use and linear response for
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large dose ranges. The disadvantages of MOSFETs include low sensitivity and angular
dependence due to their asymmetric design.
Thermoluminescent detectors (TLDs) are relative dosimeters that have sufficient sen-
sitivity for low-dose applications. These detectors are small in size and are available in
various forms for in-vivo measurements. Disadvantages that make TLDs unsuitable for
out-of-field measurements are their energy dependence and lack of real-time measure-
ment capability. TLDs have a long and time consuming readout and calibration time.
According to Rosenfeld (2002) [38], the over layer of a TLD is too thick to be able to
obtain measurements at shallow depths. A study conducted by Kry et al. (2006) [26]
measured out-of-field dose with thermoluminescent dosimeters (Harshaw, TLD-100),
where the TLDs were placed in slots at specific depths in the phantom. The TLDs were
read out by the Radiological Physics Centre (RPC, Houston TX). The RPC TLD anal-
ysis technique included multiplicative correction factors to be applied to the raw dose
to account for the fading, non-linearity and energy dependence of the TLDs [26]. Thus,
the use of TLDs is deemed unsuitable in this study for the out-of-field measurements
due to the lack of instant readout and time consuming correction factors required to be
applied to the raw dose.
Radiochromic film is used as a radiation detector by changing colour after exposure to
ionising radiation. This occurs when the photo monomer molecules in the film, which
are colourless, undergo a chemical change due to the energy transfer from the incoming
photons/particles. This colour change is what is measured to determine optical den-
sity, which is ultimately a function of the dose deposited [39]. Film is commonly used
for surface measurements, for example for patients receiving radiation therapy to the
breast, which is associated with acute and late skin toxicity [40]. EBT Gafchromic film
has been previously used to measure doses outside the treatment field by Chiu-Tsao et
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al. (2009) [41] and Van den Heuvel et al. (2012) [42]. Gafchromic is relatively insen-
sitive and the uncertainties associated with the very low doses being measured in this
study (in the order of 10 cGy) make film unsuitable.
Based on the dosimeter characteristics discussed above it was deduced that neither of
the solid state dosimeters were found to be suitable for measuring out-of-field dose.
Therefore it was decided to use ionisation chambers in our study of out-of-field dose.
Table 2.1 summarises the suitability of the most commonly used dosimeters in terms
of size, sensitivity, accuracy, cost, and applications of the dosimeter.
2.7.2 Ionisation Chambers
An ionisation chamber is a gas filled cavity encompassed by a conductive external wall
with a central collecting electrode. The wall and the collecting electrode are isolated
with a high quality insulator to lessen the leakage current when a polarising voltage is
connected to the chamber. A guard electrode is normally given in the chamber to fur-
ther diminish chamber leakage. The guard electrode intercepts the leakage current and
allows it to flow to ground, bypassing the collecting electrode. It additionally guaran-
tees enhanced field uniformity in the active or sensitive volume of the chamber, with
resulting advantages in charge collection.
An ionisation chamber is a capacitor in which leakage current is induced through the ac-
tion of the radiation beam. The current that is induced in the chamber is very small and
must be measured by a highly sensitive current measuring device such as an electrome-
ter. Electrometers are able to measure small currents, of the order of 10−9 Amperes or
less [24]. An electrometer utilised as a part of conjunction with an ionisation chamber is
a high gain, negative feedback, operational amplifier with a standard resistor or a stan-
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dard capacitor in the feedback path to quantify the chamber current or charge gathered
over a fixed time interval [24]. The power supply in an ionisation chamber/electrometer
circuits is either a stand-alone unit or forms an integral part of the electrometer. It
is therefore important that the magnitude and polarity of the voltage delivered by the
power supply can be readily changed so that the ion efficiency of the chamber could be
determined for a particular radiation beam.
Ionisation chambers can vary in size, active volume, and shape. Ionisation chambers
are produced by various manufacturers with varying sizes and active volumes ranging
from 0.1 cm3 to 1.0 cm3. Ionisation chambers can be either cylindrical or parallel plate.
A different ionisation chamber is used for a different task such as:
• Medium Volume (0.6 cm3) cylindrical ionisation chambers are used for measur-
ing dose and dose rates at reference points in a phantom for megavoltage photon
beams and electron beams above 10 MeV in order to obtain a reasonable signal
and good signal to noise ratio.
• Small volume (0.1-0.125 cm3) cylindrical ionisation chambers are used for fine
point dose measurements, PDDs and beam profiles for photon beams and for
electron beams in order to obtain good spatial resolution.
• Parallel plate ionisation chambers, incorporating a thin polarizing electrode win-
dow and a small electrode separation (typically 1 mm, for better spatial resolu-
tion) are used to measure surface dose and doses in the build-up region for photon
beams.
2.7.2.1 Cylindrical Ionisation Chambers
The most popular cylindrical ionisation chamber is the 0.6 cm3 chamber designed by
Farmer, for beam calibration in radiotherapy dosimetry. A cross section schematic dia-
Literature Review 33
gram of a cylindrical Farmer type ionisation chamber is shown in Figure 2.6.
Figure 2.6 Cross section schematic of a Cylindrical Farmer type ionisation chamber, adapted
from [24].
Cylindrical chambers are produced by several manufacturers, with active volumes be-
tween 0.1 cm3 and 1.0 cm3. They usually have an internal length no greater than 25
mm and an internal diameter no greater than 7 mm. The central electrode can be made
of aluminium or graphite. The wall material is of a low atomic number (i.e. tissue or
air equivalent), with the thickness less than 0.1 g/cm2. A chamber is equipped with a
build-up cap with a thickness of approximately 0.5 g/cm2 for calibration free in air using
Cobalt-60 radiation [24].
2.7.2.2 Parallel-plate Ionisation Chambers
Parallel-plate ionisation chambers are comprised of two plane walls, one serving as an
entry window and polarising electrode and the other as the back wall and collecting
electrode, in addition to a guard ring system. The back wall is typically a block of con-
ducting plastic or non-conducting material (usually Perspex or polystyrene) with a thin
conducting layer of graphite forming the collecting electrode and the guard ring system
on top [24]. A schematic diagram of the top view and side view of a parallel-plate ion-
isation chamber is shown in Figure 2.7 and Figure 2.8. The parallel-plate chamber is
recommended for dosimetry of electron beams with energies below 10 MeV. It is also
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used for surface and depth dose measurements in the build-up region of megavoltage
photon beams [24].
Figure 2.7 Schematic diagram of Parallel-plate ionisation chamber.
Figure 2.8 Cross section schematic of a parallel-plate ionisation chamber, adapted from [24].
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2.7.2.3 Comparison between cylindrical and parallel plate ionisation chambers
Desirable characteristics of cylindrical and parallel plate ionisation chambers are their
low energy dependence, low dose rate dependence and high sensitivity. Their small size
and portability for easy placement is convenient and their ability for instant readout al-
lows the dose delivered to be monitored while not needing to undergo procedures such
as annealing, unlike thermoluminescent dosimeters (TLDs).
Less desirable characteristics of cylindrical ionisation chambers include its asymmet-
rical design and stem since the dose response will vary with the incident angle of radia-
tion to its cylindrical axis. This is particularly noticeable at superficial and orthovoltage
radiation energies. Other less desirable characteristics of ionisation chambers include
requiring connecting cables for the set-up of the device and a high voltage supply re-
quired for the low signal readings.
Ionisation chambers have been used previously to measure out-of-field dose. In a study
by Ruben et al. (2011) [43], a Farmer-type FC65-P cylindrical ionisation chamber
(IBA Dosimetry GmbH, Schwarzenbruck, Germany) was used to measure out-of-field
dose. In another study by Kry et al. (2006) [26], a RK CC04 cylindrical chamber
(Scanditronix-Wellhofer) was used to measure out-of-field dose. Ruben et al. (2011)
and Kry et al. (2006) found that ionisation chambers were useful dosimeters for their
out-of-field measurements, due to their small size, high precision, high sensitivity, mini-
mal energy dependence and real-time measurement capability [26,43]. Therefore, based
on the characteristics discussed above, cylindrical ionisation chambers were concluded
to be the most suitable dosimeters for measurement of out-of-field dose.
Literature Review 36
Dosimeter Size Sensitivity Accuracy Important
Applications









and easy to use
High accuracy for in-
vivo dosimetry, elec-
tron scanning and small
field photon dosimetry.















ments and small field
dosimetry with high ac-
curacy.












try, and small field
dosimetry and detector
arrays.
TLD Small size 3 mm




















































acquisition of data for
planning, QA, absolute


























Summary of dosimeters in terms of size, sensitivity, accuracy, and important applications
Literature Review 37
2.8 Current Research Status of Out-of-Field Dose
Radiotherapy treatment planning systems (TPS) are not commissioned or designed for
out-of-field dose calculations [44]. Although TPS can display the dose at points far from
the treatment field, they are not utilised for calculating the out-of-field dose as extensive
discrepancies have been reported between measured doses and those calculated from
photon-beam planning systems [45–48]. Photon-beam planning systems have been re-
ported to underestimate the true out-of-field dose [42, 45, 48]. The error in the plan-
ning system is due to the underestimation and non-consideration of patient scatter and
head leakage and substantial underestimation of collimator scatter [48]. Therefore, most
planning systems do not accurately model photon or electron leakage/scatter from the
LINAC head.
Previously, there have been numerous studies completed on out-of-field dose to fetus
and OARs. Numerous options and variations of treatment sites have been looked at us-
ing 3D-conformal radiotherapy and IMRT. Several analytical and Monte Carlo models
have been developed for the calculation of out-of-field dose.
2.8.1 Analytical Models for Estimating Out-of-Field Dose
There are several different analytical models available for the calculation of out-of-field
dose. Report of AAPM Radiation Therapy Committee Task Group No.36 [9] used data
from the fetal dose from radiotherapy with photon beams in combination with math-
ematical phantoms to determine the out-of-field dose to different organs in a patient.
Another study by Van Der Giessen (2001) [49] developed a software program called
Peridose. This software was developed to calculate the dose outside the primary beam
in radiation therapy. The program allowed the easy calculation of the peripheral dose in
patients who were treated with megavoltage photon radiation. Within its constraints and
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limits, this program allowed a fairly accurate estimation of the dose at any point outside
the treatment area [49].
Furthermore, a study by Stovall et al. (2006) [50] developed an analytical model to
be used for dose calculations. Three techniques were used to estimate doses from ex-
ternal beam radiation therapy: (1) calculations in three dimensional mathematical com-
puter models, (2) measurement in anthropomorphic phantoms and (3) calculation using
a three-dimensional treatment planning computer. The study described and compared
these methods of dose estimation and discussed uncertainties in estimated organ doses
and potential for future improvement. Exponential expressions for out-of-field dose as a
function of distance from central axis and depth for both conventional and IMRT treat-
ments have been proposed by Kry et al. (2005) [25] and Taddei et al. (2013) [51],
however the accuracy of such simple expressions was found to be relatively poor and
limited to conventional fields. Generally, the currently available analytical models are
all limited to conventional fields and do not consider more sophisticated delivery tech-
niques such as IMRT and VMAT.
2.8.2 Monte Carlo Methods for Estimating Out-of-Field Dose
Monte Carlo methods are very precise methods for calculating out-of-field dose with a
well-accepted model. Monte Carlo calculations differ from analytical models as they
use the interaction models of particles to predict the path of radiation on a particle by
particle basis, giving an overall result of a radiation beam after many iterations. An
accurate Monte Carlo model should include the intricate details of the LINAC head
geometry to ensure that leakage radiation, collimator scattered radiation, and scattered
radiation during high-energy photon therapy are appropriately modeled.
Monte Carlo codes that have been used to estimate out-of-field dose include MCNP5/MCNPX
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code which was developed by Hughes et al. (1997) [52, 53], Geant4 code which was
developed by Agostinelli et al. (2003) [54] and EGSnrc code which was developed by
Kawrakow et al. (2000) [55]. Geant4 code is superior in terms of the physics mod-
eling as it can track heavy ions as well as geometry definitions in 3 dimensions and
even 4 dimensions. EGSnrc code tracks solely photons and electrons and is well suited
for many radiotherapy applications as it has been validated for out-of-field dose ap-
plications more widely than any other photon/electron Monte Carlo codes. The main
difference between these codes is the variations in the physics modeling, cross section
data, transport mechanisms and the logistics of the model. Each code is unique and
possess several advantages for its use.
A study by Kry et al. (2006) [26] developed a Monte Carlo model to calculate the
out-of-field dose. The Monte Carlo code used was MCNPX where simulations of the
out-of-field dose were made. Measurements were obtained in this study to validate the
Monte Carlo model. The study found that the average local difference between the out-
of-field doses calculated by the model compared to these measured was only 16%. This
included a range of low doses, at distances in greater than 50 cm from the central axis of
the treatment field. The out-of-field dose was seen to vary with field size and distance
from the central axis. The Monte Carlo model developed by Kry et al. (2006) [26] was
found to adequately represent a typical Varian 2100 accelerator operated at 6 MV.
Another study by Kry et al. (2007) [56] developed a Monte Carlo model to calculate the
out-of-field dose from high energy photon therapy. In this study Kry et al. (2007) ex-
panded and validated their previous Monte Carlo model for high energy 18 MV photon
therapy, including both photons and neutrons. Simulations of out-of-field high energy
photon doses were compared with measurements. The average local difference between
the calculated and measured photon dose was 17%, including a range of low doses. The
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out-of-field photon dose was seen to vary with field size and distance from the edge of
the field. The average difference between the calculated and measured neutron fluence
was 19% and agreed well with observed neutron spectra. On the other hand, the neutron
dose changed little with field size or distance from the central axis. Neutrons were the
dominant component of the out-of-field dose equivalent for shallow depths and large
distances from the edge of the treatment field. This Monte Carlo model was found to be
useful for both physicists and clinicians when assessing out-of-field doses and potential
risks.
A study by Bednarz and Xu (2009) [57] developed a Monte Carlo model to calculate
the in-field and out-of-field dose. This model was developed to understand and better
measure non-target doses due to scatter and leakage radiation from medical accelera-
tors. MCNPX code was used to develop the Monte Carlo model which defined over
100 accelerator components. Out-of-field doses were calculated and compared to mea-
sured data for both beam energies for field sizes of 4 cm x 4 cm, 10 cm x 10 cm and
20 cm x 20 cm. For all the field sizes considered in this study, the average local dif-
ference between calculated and measured dose for 6 MV and 18 MV beams was 14%
and 16% respectively. The study further determined a method for calculating neutron
contamination in the 18 MV model by comparing the calculated in-air neutron fluence
with reported calculations and measurements. The average difference between calcu-
lated and measured neutron fluence was 20%. As one of the most detailed accelerator
models, this Monte Carlo model has been combined with anatomically realistic compu-
tational patient phantoms into a computational framework to calculate non-target organ
dose to patients from various treatment plans.
Overall, the Monte Carlo models developed by Kry et al. [26,56], Bednarz and Xu [57]
have shown good agreement with measurements beyond 50 cm from the field edge.
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Simpler models that include only beam-line components have been used by Joosten et
al. (2011) [46] and Almberg et al. (2012) [58]. The study by Joosten et al. (2011) [46]
developed a simple Monte Carlo for both open and wedged fields that were validated
with dose profiles measured in a water tank up to 30 cm from central axis. It was found
that differences between measured and calculated doses were comparable to other more
complex models and never exceeded 50%. The study by Almberg et al. (2012) [58] de-
veloped a simple Monte Carlo model using the EGSnrc code, where photon simulations
and dose calculations in a water tank were made. The study found that the out-of-field
dose for regions up to 20 cm from central axis will reduce by 10%-30% compared to the
linear accelerator operating with a flattening filter. The two simple models developed by
Joosten et al. [46] and Almberg et al. [58] have been noted to be capable of accounting
for the patient scatter outside the treatment field, however, they do not allow for proper
modeling of head leakage and collimator scatter. For beam-line models, good accuracy
can be achieved out to approximately 15 cm from the field edge beyond this accuracy
becomes increasingly poorer.
To develop a model that will predict the doses to the organs of interest and perform
the calculations for the region is a difficult process that requires a lot of time and effort.
This model may also only be useful for only one region of interest as it complicated to
consider other regions and sites. There are techniques to minimise non-target dose by
using others forms of treatment, changing MLC and collimator orientation, using low
energy treatment options and providing patient shielding.
Chapter 3
Experimental Challenges and
Principles of Measuring Out-of-Field
Dose
The measurement of out-of-field dose presents many challenges, which are related to
choice of the detector. The choice of an ionisation chamber for measurements was based
on the high sensitivity, high signal to noise ratio and high spatial resolution of the cham-
ber, for dose profile and depth-dose measurements. The first challenge in out-of-field
dose measurements was the extremely low signal out-of-field. A Roos chamber was
used for near surface depth dose measurements since the 0.6 cm3 ionisation chamber
could not measure depths as low as 1 mm. A waterproof 0.6 cm3 cylindrical chamber
was used inside a water tank for dose profile and depth-dose measurements since it has
a larger volume and therefore higher sensitivity than the Roos chamber. Long scanning
times and stray radiation reaching the cable was another challenge. The difficulty asso-
ciated with setting up the water tank and fitting the water tank close to the gantry and out
of the primary beam was a challenge. The implications of these challenges with dose
profile and depth-dose measurements with a cylindrical ionisation chamber and a Roos
parallel plate ionisation chamber resulted in a need for a detailed uncertainty analysis.
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An uncertainty associated with a measurement is a parameter that characterises the dis-
persion of the values and can be separated into two components based on the origin
of the sources of uncertainty, namely a random component (type A) and a systematic
component (type B) [59].
3.1 Experimental Uncertainties: Type A Uncertainties
Type A uncertainties are attributed to random errors. The method of Type A uncertain-
ties is based on statistical analysis of a series of observations, it is the standard deviation
based on the short-term reproducibility. Type A uncertainties are able to be picked up by
repeated measurements. One way of reducing the effect of randomness is to take a large
number of readings and calculate the average. Statistically, this is reducing the standard
deviation of the mean by increasing the sample size. Random uncertainty can never be
eliminated completely, therefore a statistical model can be used to estimate them [60].
3.2 Experimental Uncertainties: Type B Uncertainties
Type B uncertainties are attributed to systematic errors. The method of type B uncertain-
ties is not based on a statistical analysis of a series of observations, it is an uncertainty
estimate due to all other factors which are difficult to quantify. Therefore, the sources
of measurement uncertainties that cannot be estimated by repeated measurements are
called type B uncertainties. These include not only unknown influences on the mea-
surement process but also little known effects of influence quantities such as variations
in pressure, temperature, etc. In this case, type B uncertainties could include setup
reproducibility and accuracy, spectral changes under varying conditions, uncertain elec-
tron/photon mix at shallow depths, stability of the electrometer response, for example
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drift in dark current during measurements (especially because of the low dose rate lead-
ing to low current pA instead of the usual nA, in spite of frequent zeroing of the elec-
trometer), changes in temperature and pressure between calibration and measurement
conditions, linac output variation with time (due to very long beam on times), chamber
characteristics such as stem effect or poor venting and positioning uncertainties. Im-
proving the quality of equipment can reduce the systematic uncertainty, however, it can
never be completely eliminated [60].
3.3 Combination of Type A and Type B Uncertainties
The combination of type A and type B uncertainties gives the total expanded uncer-
tainties as type A and type B uncertainties are both estimated standard deviations. The
combination of type A and type B uncertainties is given by combining the variances,
such that if uA and uB are the type A and type B standard uncertainties of a quantity,






The addition of type A and type B uncertainties in quadrature results in the total uncer-
tainty [59]. This has been performed for each chapter in this study.
3.4 Uncertainty Estimate for Measurements
An error analysis was completed for this study which consists of experiments within
solid water blocks, within liquid water tanks and on an anthropomorphic phantom.
Depth dose measurements in solid water involved recording the dose at the surface.
The type A and type B uncertainties within the experiment were accounted for in the
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error analysis. The type A uncertainties were random errors which were accounted for
by taking the standard deviation of the point dose measurements.
Type B uncertainties within the experiment were systematic errors which included the
reproducibility of the set-up. Uncertainties may have resulted from the very low output
signals measuring the out-of-field dose. Measurements were taken with a Roos chamber
since it had a good spatial resolution in the depth direction and a good signal to noise
ratio. A Roos chamber also has a small inherent effective depth of measurement.
Characteristics that were necessary for the depth dose measurements in solid water were
a detector that had a good spatial resolution in the depth direction. Hence, a Roos cham-
ber was used with a very long integration time in solid water, with only 1 mm of inherent
material. This was essential in order to have an accurate characterization of the near sur-
face dose. Therefore, the uncertainties for the solid water measurements were calculated
by the addition of type A and type B uncertainties in quadrature, which results in the
total uncertainty for each individual graph.
For the dose profile and depth dose measurements and the VMAT patient plan scans,
type A and type B uncertainties were accounted for in the error analysis. The type A
uncertainties within the experiments were random uncertainties which were extremely
small and therefore insignificant to be recorded. For the depth dose measurements, a
waterproof 0.6 cm3 cylindrical chamber was selected for measurements since it had a
high sensitivity and a good signal to noise ratio.
Initially, a 0.125 cm3 cylindrical and Roos chamber were used for the water tank scans
however, this was very challenging due to the low signal measuring a current of pA. The
0.125 cm3 cylindrical and Roos chamber had a very low signal to noise ratio and there-
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fore were not useful for the water tank scans. Hence, a 0.6 cm3 cylindrical chamber was
used instead with 1 second integration time in each position compared to the normal
0.1 second integration time in-field. The very long integration times in the water tank
resulted in each scan being up to 20 minutes long, this may have contributed to error, as
this increases the amount of stray radiation reaching the cables.
Therefore, the uncertainty estimate for the dose profile and depth-dose measurements
were determined from the addition of type A and type B uncertainties in quadrature,
which resulted in the total uncertainty for each of the measurements. The type B uncer-
tainties were determined to be 3% for one standard deviation (6% to within 95% confi-
dence interval), which contributed to the total uncertainty for each of the measurements.
For the anthropomorphic phantom VMAT measurements, a 0.6 cm3 cylindrical chamber
was used because of its minimal angular dependence around the azimuth and a good sig-
nal to noise ratio. The disadvantage of this chamber is that its geometry is not good for
near surface measurements. To determine how much build-up material was needed to
get the right effective depth, a comparison of the Roos and 0.6 cm3 cylindrical chamber
at shallow depths was done to compare the near surface dose. The comparison showed
reasonable agreement, which was sufficient for the purposes of the anthropomorphic
phantom VMAT measurements.
To compare the results with the surface dose the electron density of the wax material
was used to calculate the water equivalent depth in wax. Water equivalent depth was
determined using the effective atomic number (Z). Effective atomic number (Z) is the
atomic number of an element with which photons interact with the same way as with
the given composite material. The interaction of photons, with the photoelectric effect
is highly dependent on the atomic number (Z) of an absorbing material. Therefore,
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the effective atomic number (Z) is considered for photoelectric interactions. Mayneord











Where a1, a2, a3, ..., an are the fractional contributions of each elements to the total
number of electrons in the substance.
Example 1. Calculation of Effective Z for Wax: C25H52











Using the electron density (ρ) of the wax material, the water equivalent depth in wax











Therefore, the uncertainty estimate for the anthropomorphic phantom VMAT measure-
ments were determined from the addition of type A and type B uncertainties in quadra-
ture, which resulted in the total uncertainty for each of the measurements.
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Type of quantity or
procedure
Uncertainty Type A or Type B Uncertainty (%)






3 Spectral changes in
photon component
Type B 2%
4 Electron/photon mix at
shallow depths
Type B 3%
5 Signal to noise ratio due
to low signal and long
integration times caus-
ing drift in dark current
Type B 4%







Estimated combined Type A and Type B uncertainty to (1σ) for dose profile, depth-dose and
anthropomorphic phantom VMAT measurements using an ionisation chamber.
The type A and type B uncertainties have been explicitly separated and listed Table 3.1.
The calculation for the 6% uncertainty has been explained in the last row of the table




As the beam is incident on a patient (or phantom), the absorbed dose in the patient varies
with depth. This variation depends on many conditions: beam energy, field size, dis-
tance from source and beam collimation system. The calculation of the out-of-field dose
in the patient involves considerations in regard to these parameters and others as they
affect depth dose distribution. Hence, an essential part in the dose calculation system is
to establish depth dose variation away from the central axis of the beam.
In this chapter, depth-dose measurements at extremely shallow depths will be inves-
tigated, since the sensitive region of the eye lens is as shallow as 2.8 - 3.8 mm [2] and
CIEDs are inserted just beneath the skin at depths between 5 - 10 mm. The aim of this
chapter is to investigate the dose at shallow depths, with varying field sizes and to in-
vestigate the suitability of the parallel plate chamber for characterization of out-of-field
measurements.
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4.1 Materials
Dose measurements near the surface require good spatial resolution in the depth di-
rection, therefore a parallel plate chamber must be used. For this reason we used the
ROOS ionisation chamber. A PTW UNIDOS R© Electrometer was set at low range, cur-
rent mode and a bias voltage of 150 V to record the charge in nC range. Solid water
sheets were used as scatter material for the detectors. Ainsworth dental wax with a
density of 0.92g/cm3 was used as additional build up material for the detectors.
4.2 Methodology
4.2.1 Part I: Calibration of the Photon Beam
The first part of the experiment involved calibrating the output of the photon beam
with the Roos ionisation chamber, in solid water. In order to generate the calibration
coefficients for the Varian Clinac iX linear accelerator, a 6 MV beam was applied. The
Varian Clinac iX linear accelerator was set to reference conditions: gantry angle 0◦,
collimator angle 0◦, FSD = 100 cm, 10 cm x 10 cm field size and MLCs retracted. The
Roos chamber was connected to a power supply, set at a voltage of 150 V, with a PTW
UNIDOS R© T10001-11678 electrometer measuring the capacitor charging current. The
Roos chamber was placed at isocentre and 100 MU was delivered to the chamber in
solid water at an effective depth of dmax = 15 mm. The chamber calibration coefficients
were essential to convert the reading measurements from charge (pC) to dose (µGy/MU)
in non-reference conditions.
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4.2.2 Part II: Quantification of couch scatter
Due to the very low signal from head leakage and collimator scatter, it was essential to
minimise any scatter coming from objects in the primary radiation field, therefore there
should be no material directly in the path of the beam for these measurements. In order
to place the detectors at clinically relevant positions to measure the dose at the eye lens
and the upper chest, it was necessary to place the detectors and their associated solid
water phantoms out of field and at the appropriate locations between the gantry and
the edge of the beam. This could be achieved by having the couch out of the primary
field i.e. fully retracted or rotated to 90◦ and offset towards the gantry, but it was more
convenient to have the phantoms supported on the gantry end of the couch while the
couch was still at 0◦ and therefore in the primary beam. For the latter case, it was
important to examine the extent of the contribution of scattered dose coming from the
couch as there was a risk of the couch generating in-field scatter. To test this, out of
field measurements were performed in solid water with the couch in-field (couch angle
0◦). The measurements were then repeated without the couch in the field (couch angle
90◦). Measurements were taken at gantry angle 0◦ and 180◦, with the collimator at 90◦
at four different field sizes of 2 cm x 2 cm, 5 cm x 5 cm, 10 cm x 10 cm and 20 cm x 20
cm. The MLCs were kept at 40 cm x 40 cm at all times.
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Figure 4.1 Quantification of couch scatter: couch in primary field
Figure 4.2 Quantification of couch scatter: couch out of primary field
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4.2.3 Part III: Depth Dose Measurements with Roos Chambers
Measurements for the out-of-field depth dose were performed using two Roos parallel
plate ionisation chambers. The Roos chambers and their associated solid water phan-
toms were placed out of field and at their appropriate locations between the gantry and
the edge of the beam to simulate prostate treatments. One of the chambers was placed
at 76 cm from central axis which represented the location of the eye lens and the other
was placed 52 cm from central axis which represented the location of chest where the
CIED would be situated on a patient.
Due to there being only one slab of solid water with a cavity for the Roos chamber,
this cavity was used to place the chamber at the location of the chest. For the location
of the eye lens, a cavity was made in a gelatin slab to fit the Roos chamber. It was vital
for the gelatin to be shaped accordingly, as a lack of side scatter would result in incor-
rect measurements. Each Roos chamber has a front window of 1 mm PMMA, which
is equivalent to 1.3 mm of water. Additional layers of wax were added on top of the
chambers to increase the depth of measurement for each separate configuration. The
out-of-field measurements were taken at gantry zero, at three different field sizes: 0.5
cm x 0.5 cm, 10 cm x 10 cm and 20 cm x 20 cm. The MLCs were retracted at 40 cm
x 40 cm at all times. The position of the Roos chambers can be seen in Figure 4.3 and
Figure 4.4.
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Figure 4.3 Experimental set-up of Roos chambers
Figure 4.4 Experimental set-up of Roos chambers in relation the gantry
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4.3 Results
4.3.1 Part II: Quantification of couch scatter
Table 4.1 below quantifies the contribution of the couch scatter by having the couch in
the primary field or out of the primary field for varying field sizes. The readings below










2cm x 2cm 0◦ 4.69±0.14 4.71±0.14 +0.3%
5cm x 5cm 0◦ 4.84±0.15 4.91±0.15 +1.6%
10cm x 10cm 0◦ 5.69±0.18 5.91±0.18 +3.9%
20cm x 20cm 0◦ 9.76±0.29 9.96±0.30 +2.4%
2cm x 2cm 180◦ 1.22±0.04 1.15±0.03 −5.7%
5cm x 5cm 180◦ 1.72±0.05 1.63±0.06 −5.2%
10cm x 10cm 180◦ 3.46±0.10 3.37±0.10 −2.5%
20cm x 20cm 180◦ 10.59±0.32 10.47±0.31 −1.1%
Table 4.1 Quantification of couch scatter. Average difference = 0.8%
By examining the quantification of the couch scatter, having the couch in the primary
field or out of the primary field shows a small change in the readings. As the average
difference in the readings is less than 1%, it can be concluded that the contribution to
the scattered dose is small. Therefore, it is acceptable to have the couch either in the
primary field or out of the primary field. The small discrepancies are most likely due to
random errors in replicating the set up with and without the couch.
4.3.2 Part III: Depth Dose Measurements with Roos Chamber
Out-of-field depth dose measurements, using a Roos chamber, with varying field sizes:
0.5 cm x 0.5 cm, 10 cm x 10 cm and 20 cm x 20 cm at the location of the eye lens are
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show in Figure 4.5 and at the location of the location of the chest Figure 4.6.
Figure 4.5 Out-of-Field Depth Dose using Roos chamber, at the location of the eye lens, with
0.5 cm x 0.5 cm, 10 cm x 10 cm and 20 cm x 20 cm field sizes.
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Figure 4.6 Out-of-Field Depth Dose using Roos chamber, at the location of the chest, with 0.5
cm x 0.5 cm, 10 cm x 10 cm and 20 cm x 20 cm field sizes.
Both Figure 4.5 and 4.6 show the larger the field size the greater the out-of-field dose.
The dose is seen to be greatest at the shallowest region 1 mm and then it is seen to be
decreasing slightly as the effective depth of measurement increases.
Figures 4.7, 4.8 and 4.9 compare the out-of-field depth dose, using a Roos chamber,
with the same field size, at the location of the eye lens and chest.
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Figure 4.7 Out-of-Field Depth dose using Roos chamber, at the location of the eye lens and
chest with 0.5 cm x 0.5 cm field size.
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Figure 4.8 Out-of-Field Depth dose using Roos chamber, at the location of the eye lens and
chest with 10 cm x 10 cm field size.
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Figure 4.9 Out-of-Field Depth dose using Roos chamber, at the location of the eye lens and
chest with 20 cm x 20 cm field size.
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4.4 Discussion/Conclusion
Firstly, the quantification of the couch scatter was examined for a gantry angle of 0◦ and
180◦, with field sizes of 2cm x 2cm, 5cm x 5cm, 10cm x 10cm and 20cm x 20cm. It
was concluded that having the couch in the primary field or out of the primary field had
minimal effect on the scattered dose. The average difference of 0.8% is minimal, but the
individual differences between the same field sizes are not. Small discrepancies were
due to systematic errors in replicating the set up with and without the couch, as well as
possible changes in testing conditions i.e. pressure, temperature.
The out-of-field depth dose measurements, with the Roos chamber in solid water at
the location of the eye lens and chest, with the field size of 0.5cm x 0.5cm, 10cm x
10cm and 20cm x 20cm were examined. The depth dose curves showed the dose to be
greater near the surface. For the smaller field size of 0.5cm x 0.5cm the dose to the eye
lens was greater than the dose to the chest. For the 10cm x 10cm field size, the dose to
the chest was greater than the dose to the eye lens until 6 mm where the dose to the eye
lens became greater than the dose to the chest. The cross over in the dose distribution
is likely due to there being more attenuation of the beam by the shielding components
in the LINAC head in the direction of the chest, combined with a higher surface dose
from the scattered electrons or low energy photons at the chest. For the larger 20cm x
20cm field size, the dose to the chest was significantly greater than the dose to the eye
lens. This was primarily due to the larger area of jaw surface that can scatter radiation
outside the primary beam, thus increasing the out-of-field dose. Overall, the depth dose
curves displayed the dose to be greater for larger field sizes such as 20cm x 20cm and
10cm x 10cm, with a decreasing trend as the effective depth of measurement increases.
In conclusion, the Roos chamber was able to successfully measure the low signal (pC)
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dose at shallow depths, with varying field sizes. The Roos chamber had a good spa-
tial resolution in the depth direction, which was found to be precise and effective at
measuring the out-of-field dose.
Chapter 5
Characterisation of Out-of-Field Dose
Components
The measurement of non-target photon dose outside the treatment field poses many
unique challenges as the radiation is different outside the treatment field. Based on
the characteristics of the radiation field outside the target volume, general measurement
considerations are warranted. The aim of this chapter is to characterise the out-of-
field dose components and to examine the relative contributions of leakage and the two
components of scatter.
5.1 Materials
Dose profile and depth dose measurements were taken in 60 cm x 50 cm x 40.8 cm
motorised water tank, which was accompanied with a PTW MP3 system software, con-
nected to a PTW UNIDOS R© Electrometer, with MEPHYSTO R© mc2 software. The
MEPHYSTO R© mc2 software scan parameters were set to obtain optimal results. The
scans were taken on low range setting, SSD of 90 cm, gantry 0◦, speed 10mm/s, steps
starting from 2 mm at around 170 mm from central axis up until 300 mm from central
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axis, to obtain optimal precision and 20 mm steps at 300 mm up until around 750 mm
from central axis. A dwell time of 1 sec was set at each position which had to be much
longer than for the in-field measurements (generally 0.1 s).
Out-of-field dose profile and depth dose measurements required a detector with a high
sensitivity and minimal angular dependence for measuring very low dose in pC. A 0.6
cm3 waterproof cylindrical ionisation chamber (PTW FREIBURG, TM31010) was used
to obtain dose profile and depth dose measurements. The dose profile and depth dose
measurements were recorded with the water tank electrometer which can only provide
relative ionisation values. In order to be able to convert the profiles and depth dose mea-
surements to dose/MU, they were normalised using point dose measurements carried
out in solid water with a detector/electrometer combination whose sensitivity was deter-
mined through exposure under reference conditions. A PTW UNIDOS R© Electrometer
was set at low range, current mode and a bias voltage of 150 V to record the charge in
pC. Solid water sheets were used as build-up material for the detectors. An anthropo-
morphic pelvis phantom was used as scatter material for the dose profile and depth dose
measurements.
5.2 Methodology
5.2.1 Part I: Calibration of the Photon Beam
The first part of the experiment involved calibrating the output of the photon beam with
the 0.6 cm3 ionisation chamber, in solid water. In order to generate the calibration co-
efficients for the Varian Clinac iX linear accelerator, a 6 MV beam was applied. The
Varian Clinac iX linear accelerator was set to reference conditions: gantry angle 0◦,
collimator angle 0◦, Focus to Source Distance = 100 cm, 10 cm x 10 cm field size
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and MLCs retracted. The 0.6 cm3 cylindrical ionisation chamber (PTW FREIBURG,
TM31010) was connected to a power supply, set at a voltage of 150 V, with a PTW
UNIDOS R© T10001-11678 electrometer measuring the capacitor charging current. The
0.6 cm3 cylindrical ionisation chamber was placed at isocentre and 100 MU was deliv-
ered to the chamber in solid water at an effective depth of dmax = 15 mm. The chamber
calibration coefficients were essential to convert the reading measurements from charge
(pC) to dose (cGy/MU) in non-reference conditions.
5.2.2 Part II: Comparison with Kry et al. (2006) Out-of-field Dose
Profile Measurement
The aim of this section was to obtain out-of-field dose profiles that would reproduce the
setup of Kry et al.(2006) [26] to verify our measurement methods. To reproduce the
setup of Kry et al. (2006), out-of-field dose profile measurements were taken with a 0.6
cm3 waterproof ionisation chamber (PTW FREIBURG, TM31010) inside a water tank.
The dose profile measurements were performed at gantry angle of 0◦, collimator angle
0◦ and 100 cm SSD. The chamber was positioned at a depth of 37.5 mm and 112.5
mm, 15 cm away from central axis up until 70 cm, with each subsequent dose mea-
surement. Solid water sheets were placed under the beam to provide phantom scatter.
The dose profile measurements were compared to the results of Kry et al.(2006) [26].
Experimental set-up can be seen in Figure 5.1.
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Figure 5.1 Experimental set-up of out-of-field dose measurements, for comparison with the
results of Kry et al. (2006) [26]
5.2.3 Part III: Clinically Relevant Out-of-Field Measurements
In this section, the water tank was positioned on the gantry side of the isocentre in order
to represent the most realistic positioning of the patient with the head of the patient
close to the gantry side. The out-of-field scans were taken with a waterproof 0.6 cm3
ionisation chamber (PTW FREIBURG, TM31010) inside the water tank, 20 cm away
from central axis up until 70 cm, at depths of 5 mm, 15 mm and 37.5 mm with each
subsequent dose measurement. The source to water surface distance was set to 90 cm
SSD.The following conditions were set as the reference conditions for all experiments:
1. Gantry at 0◦
2. Collimator at 0◦
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3. Field Size: 10 cm x 10 cm
4. MLC Field Size: 10 cm x 10 cm
Figure 5.2 Experimental set-up of the out-of-field dose measurements, inside the water tank
with/out the phantom scatter
To separate the individual dose contributions of head leakage (HL), collimator scatter
(CS) and internal patient scatter (PS) the following experiments were performed.
5.2.3.1 Experiment 1: Total dose including Head Leakage (HL) + Collimator
Scatter (CS) + Patient Scatter (PS)
The total dose of the scattered radiation from head leakage (HL), collimator scatter
(CS) and internal patient scatter (PS), was obtained by performing clinically relevant
scans at a gantry angle of 0◦, at collimator angle 0◦, 45◦ and 270◦, field size of 10
cm x 10 cm and MLC field size of 3 cm x 3 cm, 6 cm x 6 cm and 10 cm x 10 cm.
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An anthropomorphic pelvis phantom was placed directly under the treatment beam to
provide phantom scatter. Separate scans were performed for each set of conditions, to
compare the different collimator angles and MLC field sizes, at varying depths, with the
presence of phantom scatter.
Total Dose = HL+ CS + PS
5.2.3.2 Experiment 2: Head Leakage (HL) + Collimator Scatter (CS)
To measure the contribution of scattered radiation from head leakage and collimator
scatter alone, the pelvic phantom was removed from isocentre, out of the treatment
beam. The water tank was positioned relative to the isocentre. The beam did not pass
through or interact with the water in the tank and therefore this eliminated the contribu-
tion of phantom scatter. The scans were performed at a gantry angle of 0◦, at collimator
angle 0◦, 45◦ and 270◦, field size of 10 cm x 10 cm and MLC field size of 10 cm x 10
cm. Separate scans were performed for each set of conditions, to compare the differ-
ent collimator angles, at varying depths, without the presence of phantom scatter. The
resultant scans only represented head leakage and collimator scatter.
5.2.3.3 Experiment 3: Phantom Scatter (PS)
To determine the contribution of phantom scatter, the scattered radiation from head
leakage and collimator scatter was subtracted from the total dose of scattered radiation.
The scans performed at a gantry of 0◦, 45◦ and 270◦, with field size of 10 cm x 10 cm
and MLC field size of 10 cm x 10 cm, without the phantom scatter were subtracted
from the scans with the phantom scatter. From this a higher uncertainty is created
than the measurements alone. The addition of the uncertainty from the total dose of
scattered radiation and the uncertainty in the scattered radiation from the head leakage
and the collimator scatter, in quadrature gives the total uncertainty for the phantom
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scatter. Therefore, the total uncertainty of the phantom scatter equals to 4.2% for one
standard deviation (8.5% to within 95% confidence interval).
5.2.4 Part IV: Calibration of Dose Profiles and Depth Dose Mea-
surements
To calibrate the dose profiles and depth dose curves, point dose measurements (Gy/MU)
with a Roos chamber were taken to obtain the absolute dose measurements. The Roos
chamber was positioned at the reference point of depth 5 mm and at a distance of 500
mm away from central axis, and it was connected to a UNIDOS R© electrometer. One
profile per set of conditions at depth = 15 mm and PDDs for all conditions (field size,
MLCs, with/out phantom scatter) were obtained. Figure 5.3 and Figure 5.4 below show
the positioning of the Roos chamber inside the water tank with and without the presence
of phantom material.
Figure 5.3 Roos chamber in solid water at depth 5 mm
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Figure 5.4 Roos chamber in solid water at depth 5 mm, with the presence of phantom scatter
5.3 Results
5.3.1 Comparison between Measurements and Kry et al. (2006)
Figure 5.5 below shows the out-of-field dose profiles from a 6 MV photon beam as a
function of distance from the central axis, at depths of 3.75 cm and 11.25 cm. This fig-
ure combines the out-of-field dose measurements with the measured and Monte Carlo
simulations from Kry et. al. (2006) [26]. The experimental results were normalised to
obtain the absolute dose in µGy/MU. The absolute dose results showed good agreement
with Kry’s et al. (2006) measured and simulated Monte Carlo out-of-field doses. This
agreement with published data verified that the measurements methods were appropri-
ate.
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Figure 5.5 Out-of-field dose profile from 6 MV photon beam measurements as a function of dis-
tance from the central axis, at depths of 3.75 cm and 11.25 cm, compared to both measurements
and Monte Carlo simulations from Kry et al. (2006) [26].
From the dose profile the out-of-field dose at 3.75 cm and 11.25 cm depth were super-
imposed at all distances from the central axis. Figure 5.5 shows how the radiation is of
high energy and is able to travel large distances. As the distance from the central axis
increases the dose decreases.
5.3.2 Separated Components: Head Leakage, Collimator Scatter
and Phantom Scatter
Clinically relevant scans were taken at a gantry angle of 0◦, at collimator angle 0◦, 45◦
and 270◦, with a field size of 10 cm x 10 cm and MLC size of 10 cm x 10 cm, with and
without phantom scatter.
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Figure 5.6 Total Scatter Contribution at depth 1.5 cm, Field size 10 cm x 10 cm, MLCs 10 cm x
10 cm. Maximum uncertainty 6% (95% confidence interval)
The total scattered radiation from head leakage, collimator scatter and phantom scatter,
is demonstrated in Figure 5.6. It can be seen that the total dose is greatest at reference
conditions.
The separated scatter components at collimator 0◦, 45◦ and 270◦, at depth 1.5 cm, MLC
size 10 cm x 10 cm, field size 10 cm x 10 cm are shown in Figures 5.7, 5.8 and 5.9
below.
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Figure 5.7 Separated Scatter Components at Collimator 0◦, depth 1.5 cm, MLCs 10 cm x 10
cm, Field size 10 cm x 10 cm. Maximum uncertainty for Total Dose and HL+CS is 6% (95%
confidence interval). Maximum uncertainty for PS is 8.5% (95% confidence interval)
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Figure 5.8 Separated Scatter Components at Collimator 45◦, depth 1.5 cm. Maximum uncer-
tainty for Total Dose and HL+CS is 6% (95% confidence interval). Maximum uncertainty for
PS is 8.5% (95% confidence interval)
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Figure 5.9 Separated Scatter Components at Collimator 270◦, depth 1.5 cm. Maximum uncer-
tainty for Total Dose and HL+CS is 6% (95% confidence interval). Maximum uncertainty for
PS is 8.5% (95% confidence interval)
The scattered radiation from the head leakage and collimator scatter alone, is demon-
strated in Figure 5.10.
Characterisation of Out-of-Field Dose Components 76
Figure 5.10 Collimator Scatter + Head Leakage at depth 1.5 cm, Field size 10 cm x 10 cm,
MLCs 10 cm x 10 cm. Maximum uncertainty for 6% (95% confidence interval)
To separate head leakage from collimator scatter and phantom scatter, the MLCs were
closed, at collimator angle 45◦ and 270◦, to block any scatter from the jaws and the
phantom. Figure 5.11 and Figure 5.12 shows the head leakage alone, at collimator an-
gle 45◦ and 270◦. The dose is highest at the shallowest depth of 5 mm.
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Figure 5.11 Head Leakage: Out-of-field dose profile showing the effect of closing the MLCs
at collimator 45◦, Field size of 10 cm x 10 cm. Maximum uncertainty 6% (95% confidence
interval)
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Figure 5.12 Head Leakage: Out-of-field dose profile showing the effect of closing the MLCs at
collimator 270◦, Field size 10 cm x 10 cm. Maximum uncertainty 6% (95% confidence interval)
The difference between the total scattered radiation and scattered radiation from the
head leakage and collimator scatter, at collimator angle 0◦, 45◦ and 270◦, gives the
phantom scatter shown in Figure 5.13.
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Figure 5.13 Phantom (water) Scatter at depth 1.5 cm, MLCs 10 cm x 10 cm, Field size 10 cm x
10 cm. Maximum uncertainty for Phantom Scatter is 8.5% (95% confidence interval)
Figure 5.13 shows the phantom scatter is greatest close to the field edge and there is no
significant change with collimator angle, because the amount of patient scatter depends
only on the size of the irradiated volume and the distance from the edge of that volume.
The difference between the scattered radiation from the head leakage and collimator
scatter and the head leakage alone, will give the amount of collimator scatter. Since
there is very little difference between the scattered radiation from the head leakage and
collimator scatter and the head leakage alone, this means that the collimator scatter is
negligible.
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5.3.3 Contribution of Phantom Scatter
To further examine the effect of the phantom scatter, out-of-field dose profiles at a depth
15 mm and 37.5 mm showed the total scatter contribution to be much greater with the
phantom than without.
Figure 5.14 Effect of Phantom Scatter: Total Scatter Contribution compared with Head Leakage
and Collimator Scatter. Conditions: Col 0◦, MLC 10 cm x 10 cm and Field size 10 cm x 10 cm.
Maximum uncertainty 6% (95% confidence interval)
Figure 5.14 shows that there is very little depth dependence. At a distance of 20 cm
from central axis there is a peak which is solely a result of head leakage and collimator
scatter, as at distances beyond 20 cm from central axis the dose drops off exponentially.
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5.3.4 Effect of Varying Depths
The Total Scatter contribution compared with Head Leakage and Collimator Scatter at
varying depths, at collimator 0◦, 45◦ and 270◦ is examined below.
Figure 5.15 Effect of Depth: Total Scatter Contribution. Conditions: Col 0◦, MLC 10 cm x 10
cm and Field size 10 cm x 10 cm. Maximum uncertainty 6% (95% confidence interval)
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Figure 5.16 Effect of Depth: Head Leakage + Collimator Scatter Contribution. Conditions:
Col 0◦, MLC 10 cm x 10 cm and Field size 10 cm x 10 cm. Maximum uncertainty 6% (95%
confidence interval)
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Figure 5.17 Effect of Depth: Total Scatter Contribution. Conditions: Col 45◦, MLC 10 cm x 10
cm and Field size 10 cm x 10 cm. Maximum uncertainty 6% (95% confidence interval)
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Figure 5.18 Effect of Depth: Head Leakage + Collimator Scatter Contribution. Conditions:
Col 45◦, MLC 10 cm x 10 cm and Field size 10 cm x 10 cm. Maximum uncertainty 6% (95%
confidence interval)
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Figure 5.19 Effect of Depth: Total Scatter Contribution. Conditions: Col 270◦, MLC 10 cm x
10 cm and Field size 10 cm x 10 cm. Maximum uncertainty 6% (95% confidence interval)
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Figure 5.20 Effect of Depth: Head Leakage + Collimator Scatter Contribution. Conditions: Col
270◦, MLC 10 cm x 10 cm and Field size 10 cm x 10 cm. Maximum uncertainty 6% (95%
confidence interval)
The Total Scatter contribution compared with Head Leakage and Collimator Scatter at
varying depths, at collimator 0◦, 45◦ and 270◦ was successfully examined. The effect
of varying depths from 5 mm, 15 mm and 37.5 mm showed that the dose is higher at
shallower depths than dmax, which is probably due to electrons.
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5.3.5 Effect of Varying MLC Field Size
The Total Scatter contribution, at depth of 5 mm, with varying MLC field sizes is shown
in Figure 5.21 below.
Figure 5.21 Effect of MLC Field Size: Total Scatter Contribution. Conditions: Collimator 0◦,
depth 5 mm, Field size 10 cm x 10 cm. Maximum uncertainty 6% (95% confidence interval)
The total scatter contribution, at a depth of 5 mm, is smaller for the 3 cm x 3 cm MLC
field size. As the MLC field size is increased, the contribution from scatter increases.
The 6 cm x 6 cm MLC field size appears to have a larger contribution than the 10 cm x
10 cm MLC field size. This is an indication of the effect of setup uncertainties on the
results, which has been accounted for.
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5.3.6 Effect of Varying Focus to Source Distance (FSD)
The Total Scatter contribution, at depths of 5 mm, 15 mm and 37.5 mm, with FSD of
the pelvis phantom moved 5 cm up, at collimator 0◦ is demonstrated in Figure 5.22.
Figure 5.22 Effect of FSD: Total Scatter Contribution. Conditions: Collimator 0◦, MLC size 10
cm x 10 cm, Field size 10 cm x 10 cm, pelvis phantom moved 5 cm up. Maximum uncertainty
6% (95% confidence interval)
The total scatter contribution, at depth of 5 mm, with FSD of the pelvis phantom moved
5 cm up compared with original position, at collimator 0◦ is demonstrated in Figure
5.23.
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Figure 5.23 Effect of FSD:Total Scatter Contribution. Conditions: Collimator 0◦, MLC size 10
cm x 10 cm, Field size 10 cm x 10 cm, FSD of the pelvis phantom moved 5 cm up compared
with original position. Maximum uncertainty 6% (95% confidence interval)
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5.4 Discussion/Conclusion
The out-of-field dose components and the relative contributions of leakage and the two
components of scatter were effectively examined.
Firstly, out-of-field dose profile measurements from a 6 MV photon beam as a func-
tion of distance from central axis, at depth of 3.75 cm and 11.25 cm were found to
be in good agreement with Kry et al.(2006) [26] measured and simulated Monte Carlo
results. The agreement with published data verified that the measured methods were
appropriate.
The total scattered radiation from head leakage, collimator scatter and phantom scat-
ter was examined at a gantry angle 0◦, at collimator angle 0◦, 45◦ and 270◦, with a field
size of 10 cm x 10 cm and MLC size of 10 cm x 10 cm, with the phantom scatter. The
total dose was greatest at collimator 0◦ and the peak observed at approximately 20 cm
away from central axis was concluded to be a result of the treatment head geometry,
namely the leakage radiation penetrating through the collimators. This leakage radia-
tion is not observed at collimator angle 45◦ and 270◦ due to the components within the
LINAC. By changing the collimator angle the high energy leakage radiation is blocked
and the collimators move to reduce the gap for leakage radiation to pass through, thus
reducing the shielding effect. Therefore, at collimator angle 45◦ and 270◦, head leakage
and collimator scatter are not the dominant source of out-of-field dose. At distances of
greater than 30 cm from central axis, head leakage and collimator scatter dominate over
phantom scatter.
The scattered radiation from the head leakage and collimator scatter alone, was ex-
amined at gantry angle 0◦, at collimator angle 0◦, 45◦ and 270◦, with a field size of 10
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cm x 10 cm and MLC size of 10 cm x 10 cm. The scattered radiation dose was great-
est at collimator 0◦ and the peak at approximately 20 cm away from central axis was
concluded to be a production of the treatment geometry, namely the leakage radiation
penetrating through the collimators. At collimator angle 45◦ and 270◦, phantom scat-
ter dominates closest to the central axis, head leakage and collimator scatter dominate
at distances greater than 30 cm from central axis. Therefore, the scattered radiation is
highest closest to the central axis and decreases exponentially with increasing distance.
Comparing the total scattered radiation with the scattered radiation from the head leak-
age and collimator scatter alone, at collimator angle 0◦, the maximum dose is 30 µGy/MU
and 17 µGy/MU respectively. Therefore, the total scattered dose is much greater than
the scattered radiation from the head leakage and collimator scatter alone. As expected,
the presence of the phantom results in an overall increase in the total scattered radiation
and this effect is most prominent closer to the central axis.
By closing the MLCs, at collimator angle 45◦ and 270◦, to block any scatter from the
jaws and removing the phantom, head leakage can be separated from collimator scatter
and phantom scatter. The out-of-field dose will be only a result of head leakage. The
head leakage dose, at collimator angle 45◦ and 270◦ is highest at the shallowest depth of
5 mm. Closing the MLCs at collimator angle 270◦, there is a peak at approximately 26
cm from central axis which represents the head leakage, due to the change in collimator
location i.e. inherent shielding within the LINAC.
Comparing the total scattered radiation with the scattered radiation from the head leak-
age and collimator scatter alone, at collimator angle 0◦,45◦ and 270◦, at depths of 5 mm,
15 mm and 37.5 mm, the dose profiles show the dose is highest at the shallowest depth
of 5 mm, which is lower than dmax. The high dose at shallow depths is probably due to
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electrons which have been scattered at the surface. At depths of 5 mm, 15 mm and 37.5
mm, the total scattered radiation is greater than the scattered radiation from the head
leakage and collimator scatter alone. The peak observed at approximately 20 cm away
from central axis, is a result of head leakage which must be of high energy, as the peak
is shifted by the same amount when phantom scatter is considered.
Examining the effect of varying depths from 5 mm, 15 mm and 37.5 mm, at collima-
tor angle 0◦, 45◦ and 270◦, on the out-of-field dose profiles with and without phantom
scatter, shows that the dose is highest at shallower depths than dmax, which is probably
due to electrons. This is important to note as the sensitive region of the eye lens where
radiation becomes of critical concern is between 2.8 - 3.8 mm and CIEDs which are
inserted just beneath the skin at depths between 5 - 10 mm are also shallow and there-
fore will be adversely affected by the high doses near the surface. Comparing the total
scattered radiation with the scattered radiation from the head leakage and collimator
scatter alone, at collimator angle 0◦, the maximum dose, at the shallowest depth of 5
mm is 32 µGy/MU and 23 µGy/MU respectively. Therefore, the total scattered dose is
much greater than the scattered radiation from the head leakage and collimator scatter
alone. As expected, the presence of the phantom results in an overall increase in the
total scattered radiation.
Examining the effect of varying MLC field sizes from 3 cm x 3 cm, 6 cm x 6 cm and
10 cm x 10 cm, at collimator angle 0◦, with phantom scatter showed that the total scat-
tered radiation dose increases with increasing field size. As MLC field size increases,
this directly increases the size of the irradiated volume. The larger the MLC field size,
the greater the phantom scatter. Therefore, out-of-field dose depends on MLC field size.
Examining the effect of varying the FSD at collimator angle 0◦ showed that the total
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scattered radiation dose increases as the position of the phantom is moved up by 5 cm
relative to the height of the water tank. Thus, as the FSD is increased, the total scattered
radiation dose is increased due to greater internal phantom scatter.
Overall, the total scattered radiation dose and the head leakage and collimator scat-
ter contribution alone were successfully separated and characterised. The peak at ap-
proximately 20 cm from central axis at collimator 0◦ is a result of the treatment head
geometry, namely the leakage penetration through the Y-jaw of the secondary collima-
tor before passing through the gap between the lateral edge of the MLC and the primary
collimator. The dominant source of out-of-field dose close to the beam edge, was found
to be internal patient scatter. The out-of-field dose depends on the distance from cen-
tral axis. Therefore, the further away from central axis, the smaller the out-of-field dose.
Conclusively, out-of-field dose is primarily highest closest to the treatment field where
phantom scatter dominates, while further away from the field edge, at distances greater
than 20 cm, head leakage dominates. Therefore, total scattered radiation is dependent
on the distance from central axis, depth of measurement, MLC field size and shape and
the total delivered dose. Hence, the out-of-field dose could be reduced by increasing
distance from the field edge, increasing depth of measurement and decreasing MLC
field size. The relative total scattered radiation contributions would also vary with beam
energy, MU requirements of the treatment and internal components within the LINAC.
The contributions of head leakage and collimator scatter alone are also dependent on
linear accelerator and collimator design [43]. Finally, strong correlation of measure-
ments was seen between experimental measurements and other studies [26, 43]. Subtle
variations were attributed to positional misalignment of the detectors, reproducibility of
the set-up and different linear accelerator used.
Chapter 6
Out-of-Field Dose to the Eye Lens and
Chest for Clinical VMAT Treatments
For the purpose of this study, three VMAT patient plans of the prostate target volume
were used. The prostate target volume is approximately 7 cm in diameter, however this
varies from patient to patient. The dose distribution will be strongly dependent on the
Planning Target Volume (PTV) location, and the primary beam energy. The aim of this
chapter is to measure the out-of-field dose to the eye lens and chest (including patients
with pacemakers and ICDs) for patients undergoing VMAT of the prostate.
6.1 Materials
An anthropomorphic (anthro human, morphic shape, form or structure of human be-
ings) torso and head phantom was used for all irradiation VMAT plans. The positioning
of the phantom was extremely important and thus had to be kept consistent throughout
all experiments. The Radiology Support Services, INC, Long Beach, CA USA built this
phantom from a human skeleton embedded in tissue-equivalent polyurethane and cut it
into 35 slices with a thickness of 25 mm each.
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A Roos ionisation chamber and a 0.6 cm3 cylindrical ionisation chamber were used
for the comparison between the amount of wax needed to obtain equivalent depths. As
for the out-of-field dose measurements the characteristics of both the Roos chamber and
cylindrical chamber were taken into account in choosing which detector to use. Paral-
lel plate chambers are much better for near-surface measurements because of their good
spatial resolution in the depth direction, however they exhibit large angular dependence.
This was not a problem for the PDD measurements with gantry 0 in Chapter 4, how-
ever the VMAT patient plans are delivered in arcs and a parallel plate chamber would
therefore be unsuitable. Therefore, a 0.6 cm3 cylindrical ionisation chamber that has
good azimuthal angular independence was used, as long as the chamber’s long axis was
aligned parallel to the axis of gantry rotation, the arc delivery was not a problem.
6.2 Methodology
A comparison was made between PDDs measured with both the Roos chamber and
the 0.6 cm3 cylindrical chamber in order to determine how much wax to use over the
top of the 0.6 cm3 cylindrical ionisation chamber. Once this appropriate thickness of
wax was determined, the 0.6 cm3 cylindrical chamber was placed along the length of
the phantom at the location of the eye lens and chest to measure the out-of-field dose.
The ideal chamber positions were found on the phantom and were kept the same for all
experiments. An image of the full phantom is shown in Figure 6.1; the areas measured
with the ionisation chamber are marked.
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Figure 6.1 Full anthropomorphic phantom with the location of the ionisation chambers marked
To measure the dose to the critical regions of interest (the eye lens and chest), VMAT
patient plans were delivered. The VMAT plans delivered two arc rotations with different
MU at each rotation. The table below shows the arc rotation and the number of MUs
delivered at the location of the eye lens and chest. The dose was measured on a RANDO
anthropomorphic phantom with a 0.6 cm3 cylindrical chamber placed over the eye lens
and CIED region for a range of patient treatment fields. The ionisation chamber was
encapsulated by wax to represent the eye lens and CIED beneath the chest. The anthro-
pomorphic phantom was positioned in the supine position as close as possible to the
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gantry head to represent realistic patient positioning. The experimental setup is shown
in the Figure 6.2.
Figure 6.2 Positioning of the ionisation chambers on the anthropomorphic phantom
The proportion of patient scatter contributing to the total dose was determined by scan-
ning with and without scatter material in the field. This was performed by adding and
removing the pelvic region of the phantom from beneath the beam. Tables 6.1 and 6.2
show the amount of MUs and dose delivered for each arc rotation with and without the
pelvic phantom.
The dose to the eye lens and chest was calculated by removing the phantom from the
beam and irradiating air to determine the contribution of patient scatter. For this reason,
the maximum and minimum reading for regions of interest at arc 1 and arc 2 with and
without patient scatter was recorded. Addition of the maximum values gave the total
dose for both arcs, which was then multiplied by 35 to obtain the total dosage to the eye
lens and chest, for 70 Gy in 35 fractions, as this is the average total prescribed dose that
a prostate patient receives in a treatment.
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Patient Phantom Arc MU Dose(cGy)
1 Yes 1 371 0.162±0.005
1 Yes 2 312 0.147±0.004
1 No 1 371 0.154±0.005
1 No 2 312 0.137±0.004
2 Yes 1 199 0.062±0.002
2 Yes 2 339 0.115±0.003
2 No 1 199 0.062±0.002
2 No 2 339 0.114±0.003
3 Yes 1 335 0.131±0.004
3 Yes 2 443 0.189±0.006
3 No 1 335 0.126±0.004
3 No 2 443 0.181±0.005
Table 6.1 MU and dose per fraction delivered to the eye lens for three separate patient plans
Patient Phantom Arc MU Dose(cGy)
1 Yes 1 371 0.207±0.006
1 Yes 2 312 0.168±0.005
1 No 1 371 0.198±0.006
1 No 2 312 0.154±0.005
2 Yes 1 199 0.044±0.001
2 Yes 2 339 0.080±0.002
2 No 1 199 0.043±0.001
2 No 2 339 0.080±0.002
3 Yes 1 335 0.142±0.004
3 Yes 2 443 0.198±0.006
3 No 1 335 0.136±0.004
3 No 2 443 0.187±0.006
Table 6.2 MU and dose per fraction delivered to the chest for three separate patient plans
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6.3 Results
6.3.1 Comparison: Roos chamber and Cylindrical chamber
Figure 6.3 Out-of-Field Depth Dose Comparison between Roos and 0.6cm3 Cylindrical Cham-
ber, at the location of the eye lens (76 cm from central axis), with 10 cm x 10 cm field size.
Figure 6.3 shows that dose near-surface measured with the Roos and 0.6 cm3 cylindrical
chambers agree to within 3%, for depths of 6 mm and greater. This confirmed that the
0.6 cm3 cylindrical ionisation chamber could be used for measuring the dose to the eye
lens and chest, even though it is inherently less suitable for near-surface doses compared
to a Roos chamber. As discussed previously, the main advantage of the cylindrical
chamber is its angular independence, which was essential for VMAT measurements.
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Treatment Eye Lens (cGy) Error (cGy) CIED (cGy) Error (cGy)
1 10.20 0.31 12.30 0.37
2 6.20 0.19 4.30 0.14
3 10.80 0.32 11.30 0.34
Average 9.00 0.27 9.30 0.28
Maximum 10.80 0.32 12.30 0.37
Recommended Limits 50 - 100-200 -
Table 6.3 VMAT Results (70 Gy, 35 fractions)
6.3.2 Anthropomorphic Phantom Measurements
A typical VMAT prostate plan delivering 70 Gy in 35 fractions to isocentre, resulted in
a maximum of 11 cGy and 12 cGy to the eye lens and chest regions respectively, both
of which are below the recommended limits.
From Tables 6.1 and 6.2, the general trend between the MU and dose delivered to obtain
an estimate of other VMAT prostate plans based on MU is shown below.
Figure 6.4 MU and Dose to the Eye Lens
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Figure 6.5 MU and Dose to the Chest
6.4 Discussion/Conclusion
The out-of-field dose to the eye lens and the chest were measured for patient plans of
VMAT of the prostate. Conclusively, the dose to the eye lens and chest outside the ra-
diation field were measured to be well below the recommended thresholds conveyed by
ICRP [1] and EviQ [3].
Removal of the phantom from the beam reduced the dose to the eye lens and chest
by approximately 1-2%, showing that patient scatter is insignificant for the eye lens and
chest. This is due to internal patient scatter being the dominant source of radiation dose
for a distance of only 10 cm from the field edge, after which head leakage and colli-
mator scatter predominates. This would be further be influenced by the field size and
MU demand of VMAT. The relative contributions of different components of scatter and
leakage are likely to vary with field size, beam energy, MU requirements of VMAT and
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depth of measurement. Under the conditions tested, the maximum dose received by the
eye lens was 10.8±0.3 cGy and the maximum dose received by the chest was 12.3±0.4
cGy.
Overall, the results showed that the dose to the eye lens for a clinical VMAT prostate
treatment were below the recommended thresholds (11 cGy compared to 50 cGy) [1].
For the eye lens dose (with 0.00039 cGy/MU), to arrive at the recommended limit of
50 cGy, a 35 fraction plan would need 3500 MU in a single fraction. This is well
above the modulation factor expected from a clinical prostate plan. The maximum dose
to the chest was below the recommended threshold as well (12 cGy compared to 200
cGy) [3], this confirmed the results of the 2017 HRS International expert consensus
statement, which stated that the risk of failure of the CIED device is low, as there is no
evidence of damage up to 5 Gy [35]. This is positive for the introduction of VMAT for
prostate treatments at St George Cancer Care Centre.
Notably, for patients whose the dose to the eye lens or chest is of critical concern, or
whose treated volume is close to the area at risk, the dose should be measured either in-
vivo or in the phantom. Traditionally, eye lens doses have been measured in-vivo using
MV photon detectors with water-equivalent build-up of 10 mm or more, however this
study has shown that out-of-field doses are highest at the surface and fall off with depth.
It is therefore recommended that in-vivo detectors have a 2 mm build up for estimating
dose to the radiosensitive cells of the eye, particularly when used close to the field edge.
Chapter 7
Conclusion
In this thesis study, we have successfully evaluated the out-of-field doses to the critical
structure of the eye lens and the critical region of the chest (including patients with
CIEDs) for patients undergoing VMAT of the prostate at St George Cancer Care Centre.
The significant results and findings from this study include:
I. We have developed a set of reliable methods and procedures to accurately measure
the challenging out-of-field doses and quantitatively characterise their individual
dose components from a Varian iX 6 MV VMAT treatment.
Head leakage and collimator scatter have effectively been separated from patient
scatter. Results showed that at distances close to the field edge phantom scatter
was a dominant source of out-of-field, while at distances greater than 20 cm head
leakage was the dominant source of out-of-field dose. This conclusion was seen
across all the examined cases for different collimator angles, depths of measure-
ment and field sizes.
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II. The out-of-field doses to the eye lens and chest region (including patients with
CIEDs) have been accurately measured with an anthropomorphic phantom.
Using clinical patient VMAT plans the maximum dose received by the eye lens
was found to be 10.8±0.3 cGy, and the maximum dose received to the chest was
found to be 12.3±0.4 cGy. It was successfully concluded that the doses to the eye
lens and chest were well below the threshold doses of 50 cGy for eye lens and 200
cGy for CIEDs [1, 3].
Conclusively, it can be said that VMAT patients of the prostate will not be at risk of
cataracts or CIED failure as the out-of-field dose is minimal and will not be a harm to
them. This is extremely important clinically for patients where the dose to the eye lens
or CIED device is of critical concern. It is safe to undergo VMAT prostate planning
without the risk of affecting these critical regions. Oncologists can safely administer
dose without risk and be ensured of the safety and well-being of their prostate patients.
Note that these conditions only apply for 6 MV photon beams. Treatments using pho-
ton beams of energies greater than 10 MV will produce neutron contamination which is
known to be more damaging to CIEDs than photons [3, 35].
For physicists it is still a challenge to examine other sites especially where the treated
volume is close to the area at risk. In such cases the dose should be measured in-vivo or
in phantom initially before the patient undergoes treatment as the risk is still unknown.
Although treatment planning systems may be able to estimate the dose outside the re-
gion of interest they are not able to give an accurate representation of the dose at greater
distances from the field edge. In fact most planning systems do not accurately model
photon or electron leakage/scatter from the LINAC head. This work has shown that the
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dose at the surface may be higher than predicted by most planning systems.
Traditionally, eye lens doses have been measured in-vivo using MV photon detectors
with water-equivalent build-up of 10 mm or more, however this study has shown that
the out-of-field doses are highest at the surface and fall off with depth. Therefore, it
is recommended that in-vivo detectors have a 2 mm build up for estimating dose to the
radiosensitive cells of the eye, particularly when used close to the field edge.
7.1 Future Work
An initial aim of this project was to develop a model for predicting the out-of-field dose
to the eye lens and CIED for patients undergoing VMAT of the prostate. This model
would be used by radiation oncologists and physicists to look up the dose for different
cases, therefore allowing the radiation oncologists to provide the best outcome for the
patients. Future developments could involve developing a model for predicting the out-
of-field dose for patients with head & neck cancer where the treatment area is close to
the area at risk, since there is a clinical need for predicting and minimising out-of-field
doses in order to reduce the risk of cataracts or heart failure for patients undergoing
radiotherapy.
Future developments and prospects leading on from the findings of this thesis will pri-
marily be in terms of improved awareness of the contributors of out-of-field leakage and
how they can be monitored.
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